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ABSTRACT 
Atrial fibrillation and chronic heart failure represent important contributors to cardiovascular disease 
burden, with high incidence, prevalence and mortality rates. The overall objective of this thesis is to 
enhance the knowledge on what drives preferences for different health states (utilities) in patients with 
atrial fibrillation and chronic heart failure, and how health-related quality of life and utilities in turn 
influence clinical and economic outcomes.  
In Paper I, we used data from a European-wide observational study of patients with atrial fibrillation 
treated in cardiology clinics to estimate determinants of utility based on the EQ-5D. At baseline, 
increasing age, female gender, domestic status outside the own home, existing comorbidities, and 
symptoms of atrial fibrillation, chronic heart failure or angina were associated with reduced utility, 
while regular physical activity had a positive effect. At 1-year follow-up, significant determinants 
included atrial fibrillation symptoms and major adverse events, including stroke, myocardial infarction 
and chronic heart failure.  
In Paper II, we applied some of the results from Paper I in an economic evaluation of the anti-
arrhythmic treatment dronedarone based on patient-level data from the ATHENA trial. The within-
trial analysis indicated that dronedarone when used as in ATHENA is cost-effective within generally 
accepted thresholds (base case incremental cost-effectiveness ratio CAD$7560 per quality-adjusted 
life year), and that this also would hold in the light of subsequent label restrictions. 
In Paper III, we used data from the Swedish national registry on chronic heart failure, which mainly 
covers hospitalised patients, to analyse drivers of utility based on the EQ-5D. Utility at baseline was 
negatively affected by female gender, increasing age, increasing New York Heart Association class, 
preserved left ventricular ejection fraction, lung disease, diabetes, and use of nitrates, antiplatelets or 
diuretics. Higher systolic blood pressure and haemoglobin levels and use of angiotensin converting 
enzyme inhibitors/angiotensin receptor blockers or beta-blockers were associated with increased 
utility. A significant interaction between age category and functional class indicated that patients in 
the youngest age group are more severely affected by worsening functional status than older patients. 
In our data set, the ordinary least squares model performed slightly better than the two-part model on a 
population level and for capturing utility ranges. 
In Paper IV, we investigated the role of health-related quality of life measured with a generic 
instrument on clinical outcomes in patients hospitalised with systolic heart failure as part of a 
randomised controlled study in Sweden. Physical mobility was a significant independent predictor for 
all-cause and cardiovascular rehospitalisation and mortality, with every 1% worsening resulting in a 1-
2% increase in the hazard ratio of being hospitalised or dying. Emotional reactions were an additional 
independent predictor for all-cause hospitalisations, with a similar impact as physical mobility. 
Additional analyses suggest that the impact of health-related quality of life, specifically physical 
mobility, on cardiovascular mortality may be similar regardless of timing and setting of assessment.  
In summary, the studies in this thesis support the use of health-related quality of life and utilities as a 
value-added part of clinical and economic decision-making, due to their relationship with both clinical 
and economic outcomes.  
  
LIST OF SCIENTIFIC PAPERS 
I. Berg J, Lindgren P, Nieuwlaat R, Bouin O & Crijns H (2010). Factors 
determining utility measured with the EQ-5D in patients with atrial 
fibrillation. Qual Life Res; 19: 381-390. 
II. Berg J, Sauriol L, Connolly S & Lindgren P (2013). Cost-effectiveness of 
dronedarone in patients with atrial fibrillation in the ATHENA trial. Can J 
Cardiol; 29: 1249-1255. 
III. Berg J, Lindgren P, Mejhert M, Edner M, Dahlström U & Kahan T. 
Determinants of utility based on the EQ-5D in chronic heart failure patients 
and their change over time: results from the Swedish Heart Failure Registry. 
Submitted.  
IV. Berg J, Lindgren P, Kahan T, Schill O, Persson H, Edner M & Mejhert M 
(2014). Health-related quality of life and long-term morbidity and mortality in 
patients hospitalised with systolic heart failure. JRSM Cardiovasc Dis; 3: 
2048004014548735. 
 
  
CONTENTS 
1  Introduction ..................................................................................................................... 1 
2  Background ...................................................................................................................... 3 
2.1  Cardiovascular disease burden .............................................................................. 3 
2.1.1  Atrial fibrillation ....................................................................................... 3 
2.1.2  Heart failure ............................................................................................... 5 
2.2  Methodological concepts ....................................................................................... 7 
2.2.1  Health-related quality of life and utilities ................................................. 7 
2.2.2  Economic evaluations ............................................................................. 15 
2.2.3  Risk stratification for prognosis and management ................................. 21 
2.3  Review of the literature ....................................................................................... 23 
2.3.1  Health-related quality of life and utilities in atrial fibrillation ............... 23 
2.3.2  Economic evaluations in atrial fibrillation and the impact of 
utilities ..................................................................................................... 26 
2.3.3  Health-related quality of life and utilities in chronic heart failure ......... 29 
2.3.4  Impact of health-related quality of life on clinical outcomes in 
chronic heart failure ................................................................................ 33 
2.3.5  Identified knowledge gaps ...................................................................... 36 
3  Aims of the thesis .......................................................................................................... 37 
4  Materials and methods .................................................................................................. 39 
4.1  Materials .............................................................................................................. 39 
4.1.1  The Euro Heart Survey on Atrial Fibrillation ........................................ 39 
4.1.2  The ATHENA trial .................................................................................. 40 
4.1.3  The Swedish Heart Failure Registry ....................................................... 41 
4.1.4  The OPTIMAL study .............................................................................. 42 
4.2  Methods ............................................................................................................... 43 
4.2.1  Regression analysis ................................................................................. 43 
4.2.2  Cost-effectiveness analysis ..................................................................... 45 
5  Results ............................................................................................................................ 47 
5.1  Determinants of utility in atrial fibrillation (Paper I) ......................................... 47 
5.2  Role of different outcome measures in cost-effectiveness analyses of a 
new treatment for atrial fibrillation (Paper II) .................................................... 48 
5.3  Determinants of utility in chronic heart failure (Paper III) ................................ 49 
5.4  Impact of health-related quality of life on prognosis in chronic heart 
failure (Paper IV) ................................................................................................. 50 
5.4.1  Previously unpublished results: mortality impact of health-related 
quality of life measured at 1-year follow-up visit in outpatient care ..... 52 
6  Discussion ...................................................................................................................... 53 
6.1  Critical evaluation of study methods and findings ............................................. 53 
6.1.1  Representativeness of study samples ...................................................... 54 
6.1.2  Meaningfulness of health-related quality of life measurements ............ 55 
6.1.3  Considerations when using utilities from different studies .................... 57 
  
6.2  The role of health-related quality of life and utilities in public health ............... 58 
6.2.1  Health policy applications: use by payers .............................................. 58 
6.2.2  Prognostic markers in clinical practice ................................................... 61 
6.2.3  Possible use with patients ....................................................................... 61 
6.3  Suggestions for future research ........................................................................... 62 
7  Conclusions ................................................................................................................... 65 
8  Acknowledgements ....................................................................................................... 67 
9  References ..................................................................................................................... 69 
 
  
  
LIST OF ABBREVIATIONS 
AF Atrial fibrillation 
CHF Chronic heart failure 
CLAD Censored least absolute deviations 
DALY Disability-adjusted life year 
EQ-5D EuroQoL-5D 
HFPEF Heart failure with preserved ejection fraction 
HFREF Heart failure with reduced ejection fraction 
HRQoL Health-related quality of life 
HTA Health technology assessment 
HUI Health Utilities Index 
ICER Incremental cost-effectiveness ratio 
IQWIG Institute for Quality and Efficiency in Health Care 
KCCQ Kansas City Cardiomyopathy Questionnaire 
LVEF Left ventricular ejection fraction 
MLWHFQ Minnesota Living With Heart Failure Questionnaire 
NHP Nottingham Health Profile 
NICE National Institute for Health and Care Excellence 
NYHA New York Heart Association 
OLS Ordinary least squares 
QALY Quality-adjusted life year 
SF-36 Short Form-36 
TLV Swedish Dental and Pharmaceutical Benefits Agency 
WHO World Health Organization 
WTP Willingness to pay 
 
 1 
1 INTRODUCTION 
When I started working on this thesis, I had been looking for a topic that provided a 
combination of interesting theory, new developments and applications to different areas of 
health economics and health care. I have always found the area of quality of life highly 
fascinating, as it combines many interesting aspects, with its origins in philosophy and its 
applications to the fields of medicine, economics and health care, which also have given rise 
to many methodological approaches and issues. During the thesis, I have come to better 
understand the complexities and challenges in this field and how it ties into many areas 
within public health. Every thesis is of course a learning experience, and in this regard there 
have been some interesting methodological developments in the field of how quality of life 
weights, or utilities, should be analysed, which has informed the included studies on what 
drives utility in two important cardiovascular disorders.  
Figure 1 presents an attempt at schematically summarising the different areas covered by the 
thesis and some of their relationships also with other relevant topics in the field. The central 
theme is quality of life (measured and analysed in different ways), and the included studies 
seek to investigate what factors affect it in patients with selected cardiovascular diseases, and 
what role it plays in various areas of health care and public health.  
Figure 1: Conceptual positioning of the thesis, including areas and relationships 
covered by the different studies 
 
Notes: HRQOL=health-related quality of life, QALY=quality-adjusted life year 
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2 BACKGROUND 
2.1 CARDIOVASCULAR DISEASE BURDEN 
Cardiovascular diseases, covering diseases of the heart and blood vessels, remain the leading 
mortality cause globally, accounting for over 17 million deaths in 2008. Within this group, 
ischaemic heart disease and cerebrovascular diseases are the most common causes of death. 
Since 1990, mortality from cardiovascular diseases has been reduced in high-income 
countries as a result of primary and secondary prevention and improved treatment. At the 
same time, there has been a rapid mortality increase in low- and middle-income countries due 
to resource shortages and organisational challenges (World Health Organization, 2011). 
In Europe, the role of cardiovascular diseases as a cause of mortality is also pronounced, 
accounting for almost one in two deaths based on latest available years (Nichols et al., 
European Society of Cardiology, 2012). While mortality is declining in most European 
countries, disease burden remains high. In 2009, the total societal cost of cardiovascular 
diseases in the 27 member states of the European Union was estimated at €196 billion, with 
direct health care costs accounting for 54% of total costs, productivity losses for 24% and 
informal care for 22% (Leal, Luengo-Fernandez & Gray, European Society of Cardiology, 
2012).  
Apart from significant mortality and high economic costs, cardiovascular disease also leads to 
substantial reductions in health and quality of life. The World Health Organization (WHO) 
uses the disability-adjusted life year (DALY) to capture both time losses due to early death 
and time lived with reduced health compared to the norm (World Health Organization, 2013). 
In 2011, ischaemic heart disease and stroke led to 295 million DALYs lost and were amongst 
the top three causes of DALYs lost globally (World Health Organization, 2013).  
The focus in this thesis is on two cardiovascular indications that are significant due to the 
comparatively high risk for subsequent morbidity and mortality, making them important 
contributors to global cardiovascular disease burden: atrial fibrillation (AF) and chronic heart 
failure (CHF).  
2.1.1 Atrial fibrillation 
2.1.1.1 Definition and diagnosis 
AF is a cardiac arrhythmia characterised by specific electrocardiographic patterns (see e.g. 
Camm et al., 2010). Common symptoms include heart palpitations, shortness of breath, 
fatigue and weakness. The European Society of Cardiology groups AF into five types (Camm 
et al., 2010):   
 First diagnosed AF: applies to all patients who present with AF for the first time; 
 Paroxysmal AF: arrhythmia stopping by itself, mostly within 48 hours; 
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 Persistent AF: an episode lasting longer than seven days or requiring pharmacological 
or electrical cardioversion; 
 Long-standing persistent AF: AF lasting at least one year when a rhythm control 
strategy has been applied; 
 Permanent AF: arrhythmia that has been accepted by the patient and physician, 
meaning that rhythm control interventions are no longer pursued. 
In addition, AF can be asymptomatic (silent); in this case it may be diagnosed as part of an 
electrocardiogram for other reasons or may become apparent in the form of AF-related 
complications, such as stroke. Another way of classifying AF is into valvular and non-
valvular AF, i.e. depending on whether there is an underlying valvular pathology or not.  
2.1.1.2 Epidemiology and risk factors 
AF has been termed a growing global epidemic (Chugh et al., 2014; Lip, Kakar & Watson, 
2007). Global prevalence estimates based on a recent systematic literature review (Chugh et 
al., 2014) were 474 per 100 000 persons in 2010, with North America standing out as the 
region with the highest prevalence (702 per 100 000). According to this review, incidence 
rates have increased by over 25% from 1990 to 2010, to 77.5 per 100 000 person-years in 
men and 59.5 in women. At the same time, mortality has almost doubled due to the increases 
in prevalence and incidence. Since AF is an important risk factor for stroke and heart failure 
(Ball et al., 2013; Wolf, Abbott & Kannel, 1991), these complications are also set to grow 
with the increasing incidence of AF.  
Two major population-based studies in the US (Framingham) and Europe (Rotterdam, The 
Netherlands) have independently shown a lifetime risk of around 25% for developing AF 
from the age of 40 years (Heeringa et al., 2006; Lloyd-Jones et al., 2004). The risk factors for 
development of AF are manifold. They include increasing age, male gender, genetic 
predisposition, and a range of cardiovascular, metabolic and inflammatory factors, such as 
hypertension, diabetes, valvular heart disease, myocardial infarction, heart failure, obesity 
and raised inflammatory markers (Kannel et al., 1998; Rienstra, McManus & Benjamin, 
2012). The rise of some of these risk factors, in particular an ageing population, increased 
obesity and hypertension, as well as improved survival with other diseases and a better 
diagnosis, are likely contributors to the rising AF incidence (Chugh et al., 2014). Similarly, as 
patients survive longer and often have other comorbid cardiovascular conditions, this may 
explain some of the increase in mortality observed especially in high-income countries.  
2.1.1.3 Management 
AF management consists of two parallel therapeutic goals: reduction of symptoms and 
prevention of severe AF complications. A cornerstone of AF therapy lies in stroke prevention 
with antithrombotic agents, including aspirin, warfarin or other oral anticoagulants. To reduce 
the risk of complications, it is also critical to treat concomitant cardiac diseases, such as 
hypertension and dyslipidaemia. Rate control is usually required to control symptoms. 
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Additional symptom relief may be needed in the form of rhythm control therapy using 
cardioversion, antiarrhythmic drugs or ablation. Recent updates of e.g. the European AF 
guidelines are reflective of several pharmacological developments in this field over the past 
decade, including the introduction of dronedarone and subsequent restrictions in its indication 
due to further study results, and the emergence of novel oral anticoagulants with improved 
safety profiles (Camm et al., 2010; Camm et al., 2012). 
Over the last decade, risk stratification for stroke and thromboembolism in AF has moved 
from the simpler CHADS2 index (which assigns one point for cardiac failure, hypertension, 
age and diabetes, and two points for stroke) to the more comprehensive CHA2DS2-VASc 
score (which covers congestive heart failure, hypertension, age ≥75 years [doubled], diabetes, 
stroke [doubled], vascular disease, age 65-74, and sex category [female]). As antithrombotic 
therapy increases the risk of bleeding, it is recommended to assess this by using e.g. the HAS-
BLED score (hypertension, abnormal renal/liver function, stroke, bleeding history or 
disposition, labile international normalised ratio, elderly [>65years], drugs/alcohol 
concomitantly) (Camm et al., 2010; Camm et al., 2012). Despite these recommendations, 
large international surveys have shown that clinical guidelines are not followed in terms of 
indicated antiarrhythmic and anticoagulation therapy (Alam et al., 2012; Nieuwlaat et al., 
2005).  
2.1.2 Heart failure 
2.1.2.1 Definition and diagnosis 
HF is a complex syndrome arising from an abnormal functioning or structure of the heart, 
hindering the heart to fill with or pump a sufficient amount of blood through the body. As 
several of its typical symptoms are relatively non-specific, it can be difficult to diagnose, and 
different diagnostic criteria exist (Roger, 2013). Key diagnostic tools include 
electrocardiogram, echocardiogram and laboratory tests. The European Society of Cardiology 
has set up the following criteria for the diagnosis of HF (McMurray et al., 2012): 
 HF with reduced ejection fraction (HFREF), traditionally also termed systolic HF: 
o Symptoms typical of HF (e.g. breathlessness, fatigue or ankle swelling); 
o Signs typical of HF (e.g. elevated jugular pressure or pulmonary crackles); 
o Reduced left ventricular rejection fraction (LVEF). 
 HF with preserved ejection fraction (HRPEF), traditionally also called diastolic HF: 
o Symptoms typical of HF; 
o Signs typical of HF; 
o Normal (≥50%) or only mildly reduced LVEF and left ventricle not dilated; 
o Relevant structural heart disease and/or diastolic dysfunction.  
In terms of LVEF, there is a “grey zone” where definitions for HFREF and HFPEF may 
differ across sources. For example, the European Society of Cardiology 2012 guidelines 
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consider LVEF between 35-50% to mostly represent mild systolic dysfunction (McMurray et 
al., 2012).  
The New York Heart Association (NYHA) classification is a separate, complementary 
grading system that focuses on severity of symptoms and physical functioning (McMurray et 
al., 2012): 
 Class I: No limitation of physical activity. Ordinary physical activity does not cause 
undue breathlessness, fatigue or palpitations; 
 Class II: Slight limitation of physical activity. Comfortable at rest, but ordinary 
physical activity results in undue breathlessness, fatigue or palpitations; 
 Class III: Marked limitation of physical activity. Comfortable at rest, but less than 
ordinary physical activity results in undue breathlessness, fatigue or palpitations; 
 Class IV: Unable to carry on any physical activity without discomfort. Symptoms at 
rest can be present. If any physical activity is undertaken, discomfort is increased.  
There are many terms to describe different stages or presentations of HF. In this thesis, the 
focus will lie on chronic HF, i.e. patients who have had the disease for some time. It should 
be noted that patients with stable CHF may still experience acute (decompensation) phases.    
2.1.2.2 Epidemiology and risk factors 
There are a sizable number of epidemiological studies in HF that are based on different 
populations in Europe and the US, including renowned cohorts from Rotterdam (The 
Netherlands), Hillingdon (UK), Framingham (US), and Olmsted County (US). Given the 
different diagnostic criteria used, figures vary across studies, but they all highlight the 
significant disease burden and important areas of unmet need. The prevalence of CHF is 
estimated at 1-2% in the Western world and rises sharply at 75 years of age, with a 
prevalence of more than 10% in those aged over 85 years (Mosterd & Hoes, 2007; 
Zarrinkoub et al., 2013). Incidence rates vary from 1.3 per 1 000 person-years in populations 
over 25 years (Cowie et al., 1999) to 14.4 per 1 000 person-years in those aged 55 years or 
above (Bleumink et al., 2004).  
Prognosis remains poor despite some advances in patient management; recently, median 
survival in hospitalised patients was reported as 1.8 years in women and 2.3 in men, and the 
1-year hospital readmission rate as around 30% (Jhund et al., 2009). While a decrease in 
incidence and mortality rates has been observed for several age groups (e.g. Barasa et al., 
2014), the disease burden remains high due to a continued and growing need for specialised 
and hospital care (Roger, 2013; Zarrinkoub et al., 2013).   
The lifetime risk for developing HF in a person aged 55 years has been reported as between 
20-30% (Bleumink et al., 2004; Lloyd-Jones et al., 2002). Risk factors for HF include 
myocardial infarction, hypertension, obesity, valvular heart disease, genetic predisposition, 
renal dysfunction and obstructive pulmonary disease. AF has also been shown to be 
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correlated with long-term development of CHF (Ball et al., 2013). In Western countries, the 
major causes for HF are ischaemic heart disease and hypertension (Mosterd & Hoes, 2007).  
2.1.2.3 Management 
The therapeutic options for CHF management have been relatively unchanged for the last few 
decades. More recently, new pharmacological treatment has emerged with e.g. ivabradine, 
and research activity for previously underserved patient groups, including HFPEF, has shown 
some promising clinical trial results. Recent reports from a large European registry indicate 
that treatment guidelines are largely followed, in particular in areas with clear evidence-based 
recommendations and relatively established treatment experience, such as pharmacological 
treatment of CHF (Maggioni et al., 2013).   
For patients with HFREF, disease-modifying pharmacological treatments exist in the form of 
angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers and 
mineralocorticoid receptor antagonists. In addition, symptomatic treatment with diuretics is 
common. In addition, device therapy, such as implantable cardioverter-defibrillators and 
cardiac resynchronisation therapy, may be useful in certain patient groups. In contrast, for 
HFPEF, no pharmacological therapy is available to date that has demonstrated any impact on 
morbidity or mortality. Symptomatic treatment with diuretics and management of 
comorbidities, such as hypertension, myocardial ischemia and AF, are recommended 
(McMurray et al., 2012).  
2.2 METHODOLOGICAL CONCEPTS 
2.2.1 Health-related quality of life and utilities  
In this section, terms that are important to the concepts addressed in this thesis are defined 
and placed into their wider theoretical context. As these concepts partly originate from 
different disciplines and have been used in different ways even within these, some of the 
terms do not necessarily have standard definitions. For the purposes of this thesis, the most 
relevant and appropriate definitions given the addressed research questions are provided.   
2.2.1.1 Quality of life  
Quality of life can be an elusive concept that by nature is highly subjective and therefore 
rather difficult to quantify. In this context, it is worth citing WHO’s definition of health as “a 
state of complete physical, mental and social well-being and not merely the absence of 
disease or infirmity” (Preamble to the Constitution of the World Health Organization, 
Geneva, 1948).  
The term health-related quality of life (HRQoL) is used to distinguish between quality of life 
in a wider sense and the more specific health care and clinical setting. Generally, HRQoL is 
seen as multidimensional concept, covering several aspects (domains). This is an important 
difference compared to single-item health status questions, which nevertheless may have a 
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broader scope than HRQoL in that they refer to all components of health as defined by the 
WHO.  
Several theoretical HRQoL models have been proposed to illustrate the relationships between 
different related aspects. The most frequently used model was proposed by Wilson and 
Cleary in 1995 (Wilson & Cleary, 1995); it conceptualises the relationships between overall 
quality of life and different measures of health, covering biological and physiological 
variables, symptom status, functional status and general health perceptions.  
2.2.1.2 Health-related quality of life instruments 
Given its subjective nature, HRQoL should ideally be measured by asking patients or the 
individuals affected. A multitude of instruments exist for this, which can cover different 
domains of HRQoL, such as general health, physical functioning, social functioning, 
emotional or mental well-being, but also existential questions. Two major types of 
instruments are of primary interest in this thesis: 
 Generic instruments, which are sometimes grouped into general health profiles and 
preference-based measures;  
 Disease-specific instruments.  
Additionally, other types of instruments exist, e.g. those specific to certain symptoms or 
domains (well-known examples include the Hospital Anxiety and Depression Scale or Beck 
Depression Inventory).  
Generic instruments are intended as general measures of HRQoL that can be applied across 
different diseases and types of patients, and thus seek to capture a comprehensive range of 
generally relevant HRQoL domains in their assessment. The most established generic health 
profile is the Short Form (SF)-36 (Ware, Jr. & Sherbourne, 1992). It consists of 36 questions 
covering eight domains: physical functioning, role-physical, bodily pain, general health, 
vitality, social functioning, role-emotional and mental health. The questions have between 
two and six response categories. Responses are scaled from 1 (worst) to 100 (best) per 
domain; additionally, two summary measures called Physical and Mental Component Scores 
can be derived.  
Another example of a general health profile is the Nottingham Health Profile (NHP), which 
was developed to capture subjective health status as part of health surveys (Coons et al., 
2000; Hunt et al., 1980). It contains 38 questions covering six domains: sleep, pain, emotional 
reactions, social isolation, physical mobility and energy. Each question has two response 
levels (yes/no); answers are converted to a scale from 1 (best) to 100 (worst) per domain. 
Floor effects have been observed, i.e. a relatively large proportion of respondents tends to rate 
themselves as being in full health (which in this case is the lower end of the scale) (Coons et 
al., 2000).  
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Preference-based generic measures are of particular interest in a health economic context, as 
they allow conversion of multidimensional responses to a single index score (utility) that 
incorporates preferences between health states on a standardised scale ranging from 1 (full 
health) to 0 (dead). Although information from general health profiles and disease-specific 
instruments may be converted into preference-weighted index scores by mapping functions 
for different health states, this raises certain methodological issues which cannot necessarily 
be resolved in a straightforward manner. The most commonly used and important generic 
instruments with existing preference scores for health states that will be discussed here are the 
following: 
 EuroQoL EQ-5D; 
 SF-6D; 
 Health Utilities Index-Mark 3 (HUI-3). 
The EuroQoL EQ-5D was developed as a concise multidimensional instrument, covering five 
attributes: mobility, self-care, usual activities, pain/discomfort and anxiety/depression 
(Brooks, 1996). In the established 3-level version, each dimension is rated on a scale of 1=no 
problems, 2=some problems and 3=extreme problems. In an effort to improve sensitivity, a 5-
level version has more recently been developed, for which valuation work is ongoing.   
Algorithms for converting responses on the EQ-5D to a single index score exist for a range of 
countries across the world, with the most referenced being the one developed for the UK 
(Dolan, 1997). Depending on the algorithms used, it is possible to obtain negative utilities 
(bounded at -1), which denote health states considered worse than death. The EQ-5D is 
associated with clear ceiling effects, indicating a difficulty of distinguishing between health 
states close to perfect health (Brazier et al., 2004).  
A review of utilities obtained from the EQ-5D in cardiovascular disorders (Dyer et al., 2010) 
found the instrument to have overall satisfactory psychometric properties in these types of 
indications, including convergent and discriminative validity, reliability and responsiveness. 
By nature, it is less sensitive to clinical changes than disease-specific instruments. The 
dimensions most affected by cardiovascular diseases were pain/discomfort, followed by usual 
activities and mobility (Dyer et al., 2010).  
The SF-6D was developed to allow derivation of utility weights from the SF-36 (Brazier, 
Roberts & Deverill, 2002). It uses six dimensions of the SF-36 by excluding general health 
and combining physical and emotional roles in one dimension. In contrast to the EQ-5D, its 
index scores cannot be negative (Richardson et al., 2014). Moreover, it is associated with 
floor effects, indicating a lack of sensitivity in distinguishing between the most severe health 
states (Brazier et al., 2004).  
The HUI system uses preferences according to von Neumann-Morgenstern utility theory 
(discussed in Section 2.2.1.3). The HUI-3 is recommended as the primary version to be used 
(Drummond et al., Oxford University Press, 2005). It covers eight dimensions of health, 
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including vision, hearing, speech, ambulation, dexterity, emotion, cognition and pain 
(Furlong et al., 2001). Similar to the EQ-5D, it is associated with ceiling effects (Hatoum, 
Brazier & Akhras, 2004) and it is possible to obtain negative utilities (Furlong et al., 2001).  
Table 2 summarises key characteristics of the three generic health status classification 
systems with existing preference scores discussed above. The valuation techniques that have 
been used for the different instruments are explained further in Section 2.2.1.4. There are 
clearly marked differences in methods across the instruments, including coverage of different 
health states, use of different elicitation methods and sources for preferences, as well as 
different statistical modelling techniques. Therefore, it is natural that these methods result in 
different utilities even when used to measure the same health states, as has been shown in 
various studies (e.g. Richardson et al., 2014).   
Table 2: Description of key generic preference-based HRQoL instruments 
 EQ-5D SF-6D HUI-3 
Main reference Brooks, 1996 Brazier et al., 2002 Furlong et al., 2001 
Number of items 
(questions) 
5 11 8 
Dimensions/ 
attributes 
5 - mobility, self-care, 
usual activities, 
pain/discomfort, 
anxiety/depression 
6 - physical 
functioning, role 
limitations, social 
functioning, pain, 
mental health, vitality 
8 - vision, hearing, 
speech, ambulation, 
dexterity, emotion, 
cognition, pain 
Response levels per 
question 
3 categories (EQ-5D-3L) 
5 categories (EQ-5D-5L) 
4-6 categories 5 or 6 categories 
Number of possible 
health states 
243 (EQ-5D-3L) 18 000 972 000 
Valuation 
techniques used 
Time trade-off, visual 
analogue scale 
Standard gamble Standard gamble, 
visual analogue scale 
Conversion method 
to single index 
score 
Econometric modelling Econometric 
modelling  
Multiplicative multi-
attribute utility 
function 
Other 
characteristics 
Ceiling effects 
Negative index scores 
possible 
Floor effects 
Index score cannot be 
negative 
Ceiling effects 
Negative index 
scores possible 
Compared to generic instruments, disease-specific measures are inherently more responsive 
to changes in the studied condition as they are designed to cover areas affected by the disease. 
However, they usually do not provide comprehensive measures of HRQoL as is required for 
economic evaluations, nor can the answers readily be converted to preference-weighted index 
scores.   
In AF, there has until recently been a lack of comprehensive disease-specific HRQoL 
instruments. The Symptom Checklist is a symptom scale focusing on frequency and severity 
of symptoms and has often been used in AF (Coyne et al., 2005). Recently, there has been 
development work for at least two new, more comprehensive HRQoL instruments 
specifically addressing issues in AF: the Atrial Fibrillation-Quality of Life (AF-QoL) 
questionnaire with 18 questions covering three domains: psychological, physical and sexual 
activity (Arribas et al., 2010); and the Atrial Fibrillation QualiTy-of-life (AFEQT) 
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questionnaire with 20 items covering four domains: symptoms, daily activities, treatment 
concerns and treatment satisfaction (Spertus et al., 2011).  
In HF, a number of disease-specific instruments have been developed (Berry & McMurray, 
1999; Garin et al., 2009). The most frequently used instrument in clinical trials is the 
Minnesota Living With Heart Failure Questionnaire (MLWHFQ), which consists of 21 items 
covering symptoms and signs, physical activity, social interaction, sexual activity, work and 
emotions. The Chronic Heart Failure Questionnaire (CHFQ) contains 20 items covering four 
domains: dyspnoea, fatigue, emotion and environmental mastery. More recently, the Kansas 
City Cardiomyopathy Questionnaire (KCCQ) has emerged as another useful alternative; it 
comprises 23 items covering physical function, symptoms, social function, self-efficacy and 
quality of life (Eurich et al., 2006).  
2.2.1.3 Utilities and the link to QALYs 
The topic of preference-based generic measures leads to other central concepts for this thesis, 
namely utilities and quality-adjusted life years (QALYs). Utility theory as it is used in health 
economics is based on von Neumann-Morgenstern’s theory of rational decision-making 
under uncertainty (Drummond et al., Oxford University Press, 2005). This theory is centred 
on three axioms (normative assumptions) regarding preferences: transitivity, independence 
and continuity. Transitivity means that if an uncertain prospect a is preferred over another 
prospect b, which in turn is preferred over a third prospect c, then a is preferred over c. 
Similarly, if there is indifference between a and b as well as b and c, then the same holds for 
a and c. Independence means that there should be indifference between an uncertain prospect 
consisting of a single outcome and an equivalent prospect consisting of two outcomes with 
the same overall probability. Continuity means that if between three outcomes x, y and z, x is 
preferred over y, which in turn is preferred over z, then there exists a probability p at which 
there is indifference between experiencing y with certainty or experiencing the uncertain 
prospect of either outcome x with probability p or outcome z with probability 1-p.   
As defined by Drummond and colleagues (Drummond et al., Oxford University Press, 2005), 
preference is a broader term that encompasses both utilities (obtained for uncertain outcomes) 
and values (obtained for certain outcomes). There also is a distinction between preferences 
derived from a scaling exercise (e.g. rating scale, visual analogue scale) or making a choice 
(e.g. time trade-off, standard gamble). Only the standard gamble (discussed further in Section 
2.2.1.4) captures risk attitude and thus is the only method that formally produces utilities as 
defined by von Neumann-Morgenstern.  
Utilities are an essential component for the calculation of QALYs, which are used as a 
common outcome measure in health economic evaluations (discussed further in Section 
2.2.2). The underlying concept of QALYs is that an individual’s health states change over 
time, and that health states can be valued by multiplying their duration with a corresponding 
quality weight (utility). As opposed to HRQoL, utilities thus assign values to health states. 
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The overall experience of health can then be quantified by summing up the values for the 
different health states over time (Weinstein, Torrance & McGuire, 2009).  
The QALY weights (utilities) reflect preferences for the relevant health states. They are 
anchored at 1 (perfect health) and 0 (death or health state considered equal to death in the 
view of the respondent), meaning that negative QALY weights are theoretically possible. For 
their use in economic evaluations, QALY weights need to fulfil the properties of an interval 
scale (Drummond et al., Oxford University Press, 2005). Figure 3 illustrates the concept of 
QALYs in the context of comparing different treatment alternatives, as well as the role of 
utilities for obtaining QALYs.  
Figure 3: Concept of quality-adjusted life years and gains from treatment 
interventions 
 
Notes: QALY=quality-adjusted life year 
From a methodological point of view, QALYs need to meet three conditions to qualify as a 
von Neumann-Morgenstern utility function (Drummond et al., Oxford University Press, 
2005):  
 constant proportional trade-off: the proportion of remaining life years that a person 
would be willing to trade against a defined improvement in quality of life is 
independent of the amount of remaining life years; 
 utility independence: preferences for gambles on quality of life are independent of the 
the amount of life years and vice versa; 
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 risk neutrality with respect to time: at a fixed level of quality of life, the utility of 
additional life years is linear with time.  
Relating to these theoretical grounds, there is considerable discussion about the shortcomings 
of QALYs and possibilities of addressing these to enhance the benefits of this universal 
outcome measure when comparing health care programmes across different diseases. A lot of 
the debate can be attributed to the gap between normative utility theory and how people 
behave and make decisions in reality. In this vein, it has been suggested that researchers may 
want to investigate “irrationality-adjusted” QALYs (Garrison, Jr., 2009). 
Some of the main criticisms of the QALY relate to the strong underlying assumption that 
health state values are independent of the duration of the health state as well as preceding or 
following health states (Tsuchiya & Dolan, 2005; Weinstein et al., 2009). There is evidence 
that suggests that people are not risk neutral with regards to time, in that the value of a health 
state is related to its duration. This can be observed both in the sense of “maximal endurable 
time” (Tsuchiya & Dolan, 2005) for severe vs. less severe health states, and in the contrasting 
phenomenon of coping mechanisms, which involve changes in valuations of the same health 
state over time. In HRQoL research, the coping phenomenon can be seen to fall under the 
broader theory of response shift (Sprangers & Schwartz, 1999).  
A reflection of the conflict between normative theory and actual behaviour is the discussion 
around the interpretation of QALYs as belonging to the realm of extra-welfarism, which 
according to Brouwer and colleagues (Brouwer et al., 2008) is differentiated from welfarism 
(where social welfare is defined as a function of only individual utility) in the following four 
ways: 
 It allows other outcomes than utilities to be taken into account; 
 It allows valuations from others than the affected individuals; 
 It allows weightings that are not preference-based; 
 It allows comparison of well-being between individuals using a range of dimensions.  
Some of these points will be touched upon in the following two subsections.  
As part of the discussion around QALYs, several alternatives have been proposed. The 
DALY (disability-adjusted life year) is the most prominent one due to its use by the WHO as 
part of its analyses of global disease burden. Compared to QALYs, DALYs focus on health 
rather than quality of life or well-being by measuring time loss due to premature death and 
time in less than optimal health (World Health Organization, 2013). DALYs have also been 
subject to considerable debate, resulting in a revised and simplified methodology in 
conjunction with the 2010 Global Burden of Disease study. According to the latest 
methodology, DALYs no longer include age weighting and time discounting, healthy life 
years lost due to disability are based on prevalence instead of incidence estimates, and they 
are adjusted for independent comorbidities. In the 2010 Global Burden of Disease study, a 
reference life expectancy at birth of 86 years has been used. Disability weights 
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(corresponding to utilities in the QALY context) have been derived as part of a large 
international study using discrete choice comparisons in individuals from the general 
population (Salomon et al., 2012). Compared to earlier studies, the new method thus leads to 
higher number of DALYs lost, with a relatively higher increase amongst younger and older 
ages. In summary, DALYs can be conceptualised as a measure of population health as 
opposed to broader aspects of social welfare. 
In the context of economic evaluations, the QALY remains at the core of the methodological 
toolkit, with ongoing discussions and research seeking to identify new methods to address the 
issues raised by different research groups. There is some consensus around establishing a 
reference case to move the field forward and to foster wider use outside of resource allocation 
decisions (Drummond et al., 2009). Interesting research is ongoing e.g. around a revaluation 
of the UK EQ-5D tariff, which investigates multiple issues around health state valuation, such 
as duration and timing of health states (including those based on the EQ-5D-5L), methods for 
elicitation (including discrete choice experiments and methods to evaluate health states worse 
than death) and modes of administration (Mulhern et al., 2014). Moreover, the EQ-5D-5L 
development has led to establishment of a standardised international protocol proposing 
valuation methods to obtain value sets for the expanded number of health states (Devlin & 
Krabbe, 2013).  
2.2.1.4 Methods for obtaining utilities 
There are two different types of methods for obtaining utilities (Drummond et al., Oxford 
University Press, 2005):  
 Directly through preference elicitation techniques, including the standard gamble, 
time trade-off or scaling techniques (see Green, Brazier & Deverill, 2000; Torrance, 
1987); 
 Indirectly via generic preference-based HRQoL instruments, such as the EQ-5D, SF-
6D and HUI-3 (described in Section 2.2.1.2).  
The standard gamble method offers a choice between two alternatives and is directly based 
on von Neumann-Morgenstern’s utility theory. For chronic states, the alternatives consist of 
either treatment A with two possible outcomes (living in perfect health for t years with 
probability p or immediate death with probability 1-p), or treatment B with certain outcome 
of chronic disease state i for the remaining life (t years). The probability p is varied until there 
is no difference in preference between the two alternatives.  
The time trade-off method also involves a choice between two alternatives, but without using 
probabilities, thus seeking to address potential problems amongst respondents when dealing 
with the concept of probabilities. For chronic states, the alternatives would be living in health 
state i for time t (corresponding to life expectancy with the condition) until death, or living in 
full health for time x<t until death. The time x is varied until indifference between the two 
options is achieved.  
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Lastly, scaling techniques cover e.g. rating scales, category scales or visual analogue scales 
(VAS). They are generally seen as theoretically inferior to choice-based methods such as 
standard gamble or time trade-off, because of the inherent risk of scaling bias. However, their 
advantage lies in being easy and fast to administer; VAS is e.g. also part of the EuroQoL EQ-
5D system.  
2.2.1.5 Sources for obtaining utilities 
Who should be the source of preferences (or utilities) is a much-debated topic in health 
economics (Drummond et al., 2009). Traditionally, the general public has been the 
predominant source for these weights in many countries. One argument supporting this 
practice has been that in publicly financed health care systems, population-wide funding 
decisions should also be informed by the preferences of the overall population, which may (or 
may not) at some point experience the relevant health state(s). Alternatives include asking 
individuals with experience (past or current) of the relevant health state(s), which often is 
argued to be more relevant by those involved in clinical decisions. However, this approach 
may be related to problems of unwillingness to trade length of life against improvements in 
quality of life amongst people affected by illness or disability, resulting in potential 
overestimation of utilities.  
There is sizable evidence on the effect of the perspective and relevant experience on health 
state valuations. Based on an analysis of the US valuation for the EQ-5D, there was very 
limited difference in stated preferences for hypothetical health states between people with or 
without chronic illnesses (Pickard, Tawk & Shaw, 2013). This was also seen in a meta-
analysis of patient and population preferences (Dolders et al., 2006). On the other hand, the 
meta-analysis also found higher values when comparing preferences derived from patients 
with current experience of a health state to those from the general population, which would 
indicate a coping mechanism (or response shift). Therefore, the context of the decision as 
well as the theoretical or normative standpoint are important when choosing whom to ask 
(see e.g. Burstrom et al., 2014). For example, in treatment decisions, the patient could be seen 
as the most informed about the relevant health states, while for preventative programmes, 
healthy individuals part of the general public may be more relevant (although they also may 
have difficulties envisaging hypothetical health states). Moreover, different health technology 
assessment (HTA) bodies take different stances on this, with e.g. the National Institute for 
Health and Care Excellence (NICE) in the UK preferring values obtained from the general 
population (National Institute for Health and Care Excellence, 2013), while the Swedish 
Dental and Pharmaceutical Benefits Agency (TLV) favours experience-based values 
(Tandvårds- och Läkemedelsförmånsverket, 2003).  
2.2.2 Economic evaluations 
In this section, the main principles for economic evaluations and cost-effectiveness analysis 
are discussed. In summary, economic evaluations can be defined as “the comparative analysis 
of alternative courses of action in terms of both costs and their consequences” (Drummond et 
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al., Oxford University Press, 2005). As part of efforts to make systematic and rational 
judgements on how best to allocate limited resources between a growing number of 
therapeutic alternatives, economic evaluations have become an important element of the 
decision-making process by many HTA authorities across the world.  
2.2.2.1 Types of economic evaluations 
There are four main types of economic evaluations, which differ in how they define and 
measure the consequences, or effects, of the studied treatment alternatives:  
 Cost-minimisation analysis: the consequences are considered to be the same, and only 
costs are compared. This type of evaluation can be considered as a more limited 
analysis of only costs, given that the alternatives do in fact have the same effect; 
 Cost-effectiveness analysis: the consequences are made up of only a single effect that 
is the same for both alternatives. The effect is measured in natural units, e.g. units of 
lipid reduction (mmol/L), life years gained, number of events avoided, etc.; 
 Cost-utility analysis: the consequences can be made up of either single or multiple 
effects, which do not need to be the same for both alternatives. The outcomes are 
usually measured in QALYs (see Section 2.2.1.3); 
 Cost-benefit analysis: this widens the cost-utility concept to the measurement of 
consequences in monetary units.  
The focus in the literature, as well as this thesis, is generally on cost-effectiveness and cost-
utility analysis. In particular, cost-utility analysis using QALYs is often recommended as the 
“reference case” by different authorities or research groups (e.g. National Institute for Health 
and Care Excellence, 2013; Siegel et al., 1997).  
2.2.2.2 The question of perspective 
Regardless of the type of analysis and specific method chosen, all economic evaluations 
should start with a formulation of the decision problem – namely what is being compared and 
from which perspective. The most appropriate comparison from the viewpoint of a decision-
maker is between a new treatment (which may be a pharmaceutical, medical device, 
vaccination programme or other health care intervention) and standard practice (which often 
is something else than “no treatment”).   
The analysis perspective is essential, as it determines which costs and effects are included in 
the evaluation. The two main approaches are a societal perspective or a payer/health care 
perspective. In a societal perspective, all effects (in terms of costs and health outcomes) of an 
intervention should be included, regardless of where they occur. In a payer/health care 
perspective, costs that are not paid by the health insurance system are not included in the 
calculations. The stance on which perspective to use differs across bodies, with e.g. the US 
Panel on Cost-effectiveness in Health and Medicine designating the societal perspective as 
the “reference case” (Siegel et al., 1997), while e.g. NICE in the UK considers the payer and 
personal social services perspective to be most relevant (National Institute for Health and 
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Care Excellence, 2013), or the Canadian Agency for Drugs and Technologies in Health 
(CADTH) that of the publicly funded health care system (Canadian Agency for Drugs and 
Technologies in Health, 2006).   
The types of costs can be grouped into the following categories: 
 Direct health care (medical) costs, e.g. hospital care, outpatient visits, diagnostic tests, 
drug costs; 
 Direct non-medical costs, e.g. transportation costs, social services; 
 Indirect costs, which cover productivity losses, e.g. short-term work absence, long-
term sick leave, early retirement;   
 Informal care (cost of caregiver time) – depending on school of thought, these can be 
measured either as a direct (replacement) or indirect (productivity) costs. 
To obtain costs, resources should be valued at their market prices, which are deemed a 
suitable representation of opportunity cost, i.e. the value of the benefits that cannot be 
realised because the resource is not available for its best alternative use (Drummond et al., 
Oxford University Press, 2005). 
Another important component of economic evaluations is the time horizon during which the 
costs and effects are measured. Ideally, it should be sufficiently long to capture all relevant 
costs and effects, also those resulting from the given condition in the future.  
2.2.2.3 Incremental cost-effectiveness ratios 
In all types of economic evaluations (except cost-minimisation analysis), the concept of an 
incremental cost-effectiveness ratio (ICER) plays a central role. The ICER is defined as the 
ratio between the incremental costs and the incremental effects of an intervention A vs. its 
comparator B:  
ICER = (Costs A – Costs B ) / (Effects A – Effects B).  
The ICER can be illustrated in relation to the possible results that may be obtained when 
comparing two mutually exclusive treatment alternatives. The differences in costs and effects 
can be plotted on the so-called cost-effectiveness plane (Figure 4).  
Depending on which quadrant the results lie in, different decisions may be taken: 
 Quadrant I: A costs more than B and is more effective. The decision whether it can be 
considered cost-effective or not depends on the willingness to pay (WTP) per unit of 
effect gained – if the ICER is below a defined threshold WTP (represented by a 
dotted line in the graph), then A would be cost-effective; 
 Quadrant II: A costs more than B and is less effective, i.e. should not be adopted. In 
this case, A is said to be dominated by B (or B is the dominant alternative); 
 Quadrant III: A costs less and is less effective than B. As in Quadrant I, the decision 
depends on whether the ICER falls below a defined WTP threshold; 
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 Quadrant IV: A costs less than B and is more effective, i.e. should be adopted. In this 
case, A is the dominant alternative.  
Figure 4: The cost-effectiveness plane 
 
Notes: ICER=incremental cost-effectiveness ratio 
2.2.2.4 Trial-based analyses vs. decision-analytic modelling 
Obtaining reliable ICER estimates is at the heart of numerous health economic guidelines, 
including those by the International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) (Caro et al., 2012; Ramsey et al., 2005). Attention needs to be given to 
conceptualising the decision problem, development of analytical strategy, derivation or 
estimation of input values and assessment of uncertainty. It should be noted that various 
analytical approaches and data tend to be used as complementary pieces of evidence 
considered by decision-makers. There is no single “one size fits all” solution, which reflects 
the complexities of reality in this field. There are e.g. potentially many different sources for 
costs and effects, both with and without the new treatment. Also, the chosen perspective and 
time horizon tend to require combinations of different sources and assumptions.  
There has traditionally been a differentiation between cost-effectiveness (or cost-utility) 
analyses performed alongside clinical trials, so-called trial-based analyses, and analyses based 
on decision-analytic models. Trial-based analyses are usually performed on the basis of 
patient-level data directly collected as part of a (mostly randomised controlled) clinical trial, 
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focusing specifically on the treatment options studied and the costs and effects observed 
during the trial. The availability of patient-level data represents a valuable advantage for 
statistical analyses, as it allows addressing skewed cost data and obtaining confidence 
intervals (uncertainty estimates) for ICERs. When based on a randomised controlled trial, 
these analyses also have the benefit of having high internal validity, as potential confounders 
influencing treatment decisions have been removed. Nevertheless, there are a number of 
potential caveats to take into consideration (as outlined in e.g. Drummond et al., Oxford 
University Press, 2005 and Ramsey et al., 2005):  
 Efficacy vs. effectiveness: clinical trials are designed to measure efficacy, i.e. the 
therapeutic effect that can be attributed purely to treatment, thus requiring control of 
many external factors. This means that data need to be complemented by other 
evidence on real-world effectiveness; 
 Selection of patient population: inclusion criteria for clinical trials tend to be rather 
specific, potentially leading to difficulties when seeking to generalise trial results to 
other patient groups; 
 Relevance of comparator therapy: many randomised controlled trials use placebo as 
the comparator, while more often than not, standard of care in clinical practice 
includes active treatment(s); 
 Protocol-driven costs and outcomes: clinical trials have predefined schedules of 
assessment, which may lead to additional costs; better compliance than in clinical 
practice may also lead to different outcomes. Related issues are to what degree the 
primary outcome (e.g. a combined endpoint) is informative for a health economic 
evaluation, and whether the duration of follow-up is sufficiently long to capture 
events of interest after the endpoint has been achieved;  
 Multinational clinical trials: differences in patient populations, treatment practices and 
health care systems need to be tested for and potentially taken into account (e.g. 
through hierarchical modelling, see Manca, Sculpher & Goeree, 2010);  
 Censored cost data: contrary to time to event data, cost data may not be censored at 
random in clinical trials, as patients accrue costs at different rates depending on their 
disease severity. Different methods exist to take this into account, e.g. assuming 
random censoring (Ramsey et al., 2005) or using non-parametric methods (Raikou & 
McGuire, 2004).  
“Pure” trial-based analyses may be extended to incorporate some modelling approaches, in 
particular regarding extensions beyond the trial duration to measure long-term outcomes of 
interest in economic evaluations. Prediction of survival beyond the trial duration may be done 
through parametric, semi-parametric or non-parametric methods (Gerdtham & Zethraeus, 
2003); in all cases, the impact of assumptions should be tested through sensitivity analyses.  
Decision-analytic modelling seeks to address the issues encountered when using single 
clinical trials as the basis for health economic evaluations through e.g. combination of data 
from different sources (such as meta-analysis for treatment effects) and extrapolation of costs 
 20 
and effects beyond the trial setting. Models use a mathematical framework to approximate a 
representation of reality, which requires simplification and assumptions. Many different 
modelling techniques exist, depending on the complexity of the decision problem and 
required model structure (Caro et al., 2012): 
 Cohort models: involve transitions between health states by modelling cohorts of 
patients; these include simpler decision trees and more complex Markov models; 
 Microsimulation models: involve transitions between health states by modelling 
individuals; these allow more complex patient histories to be taken into account than 
practicable with cohort models; 
 Discrete event simulation: allows time to event to be modelled stochastically, i.e. not 
using fixed time intervals; 
 Dynamic disease models: suitable for capturing transmission mechanisms in e.g. 
infectious diseases; 
 Hybrid models: combinations of different techniques may be used, e.g. combining 
health states and events to allow flexible handling of time dimension.  
Given the potential complexity of models, clarity in design, implementation and 
communication is highly important to produce credible and valuable evidence for decision-
makers. Best practice modelling guidelines provide detailed recommendations around these 
topics, including model calibration, validation of results with clinical and health economic 
experts as well as existing evidence, and transparency in reporting (Caro et al., 2012).  
2.2.2.5 Evaluating uncertainty in economic evaluations 
Uncertainty around cost-effectiveness results can stem from a variety of sources, including 
methodological choices, data inputs, a need to extrapolate results over longer time horizons or 
to apply the results in another setting. Sensitivity analyses can illustrate the impact of 
different assumptions regarding structure and input parameters on results. Uncertainty in 
input parameters can also be assessed using probability distributions for key inputs, including 
costs, outcomes and treatment effects (so-called probabilistic sensitivity analysis). Where 
patient-level data is available, statistical methods such as bootstrapping can be used to capture 
sampling variation.  
The results of probabilistic sensitivity analyses can be presented in a number of ways, 
including confidence intervals around the ICER and cost-effectiveness acceptability curves. 
In a Bayesian framework, a cost-effectiveness-acceptability curve shows the probability that 
a treatment is cost-effective compared to its comparator at different thresholds of WTP for 
additional units of effect (Drummond et al., Oxford University Press, 2005; Zethraeus et al., 
2003). It is thus a useful illustration of the uncertainty underlying a decision. Although its 
concept is often illustrated by a smooth increasing curve asymptotically approaching 1, it is in 
fact not a cumulative distribution function and can take many functional forms (Fenwick, 
O'Brien & Briggs, 2004). Related to this concept is a wealth of studies seeking to establish 
the WTP for a QALY (also termed cost-effectiveness thresholds) as the most common 
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outcome measure in economic evaluations (see e.g. review by Ryen & Svensson, 2014), and 
a debate about whether and how these thresholds should be applied (e.g. Eichler et al., 2004; 
Gafni & Birch, 2006).  
2.2.3 Risk stratification for prognosis and management 
In this section, the focus lies on the use of HRQoL in a clinical decision-making context. As 
outlined earlier, HRQoL is an important component of disease burden, and it has been 
described and analysed with different research objectives in mind. Apart from being an 
outcome measure for a disease (and potentially economic evaluations), it can also be studied 
as a potential driver of other outcomes, such as disease progression or death. These kinds of 
prediction models aim to classify patients according to different levels of risk for an outcome 
of interest, and serve to target the intensity of treatment and follow-up. They thus present an 
important tool for clinical management, and can ultimately aid in reducing disease burden. 
Risk prediction can also be useful for identifying patient groups most likely to benefit from 
new treatments, e.g. as part of clinical trials. These models can cover a range of different 
factors, often focusing on demographic, clinical and laboratory values. For uptake in clinical 
practice, they need to be simple to use, be based on standard available data, have been 
validated in external data sets and have shown good predictive ability (calibration).  
The interest in identifying a simple prognostic measure in several chronic diseases is reflected 
in the sizeable number of studies that have investigated the impact of self-reported health 
status (using a single question or more elaborate HRQoL instruments) on e.g. mortality. For 
example, in CHF and coronary artery disease, physical health status independently impacted 
mortality and hospitalisation outcomes in the majority of 34 studies covered by a systematic 
review (Mommersteeg et al., 2009). Other examples include oncology, where HRQoL has 
been shown to be a predictor of mortality in numerous indications (Steel et al., 2014); in 
arthritis, physical and mental health components have been shown to be significant drivers of 
resource utilisation and mortality (Singh et al., 2005).  
In AF and CHF, risk prediction models commonly used today do not include HRQoL, but 
focus mostly on clinical measures. A key prognostic model in AF is the CHA2DS2-VASc 
score which stratifies patients according to their probability of experiencing a stroke based on 
several risk factors. As illustrated in Figure 5, based on the resulting risk score, different 
levels of antithrombotic treatment are recommended (e.g. ESC guidelines).  
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Figure 5: Risk stratification of AF patients for antithrombotic treatment using the 
CHA2DS2-VASc score (adapted based on ESC 2010 guidelines - Camm et al., 2010) 
 
Notes: TIA=transient ischaemic attack 
In CHF, several prognostic models for predicting mortality risk have been developed. A well-
known example is the Seattle Heart Failure model, which predicts mortality over 1-3 years 
(Levy et al., 2006). It was originally derived based on 1125 patients with HFREF 
(LVEF<30%) and subsequently validated in a broad range of populations; however, a recent 
systematic review found the external validations to indicate poor to acceptable discrimination 
and questionable calibration (Alba et al., 2013). Moreover, it covers 24 clinical, 
pharmacological, device and laboratory variables, which may not always be available in 
routine clinical care, e.g. lymphocyte counts or uric acid.  
More recently, a new risk score (MAGGIC) has been developed for 3-year CHF mortality 
based on a meta-analysis of data from 39 372 patients in 30 studies, covering a 
comprehensive spectrum of patient types, including those with HFPEF (Pocock et al., 2013). 
The risk score is based on 13 prognostic markers that are deemed to be readily available in 
clinical practice: age, LVEF, NYHA class, serum creatinine, diabetes, beta-blockers, systolic 
blood pressure, body mass index, time since diagnosis, smoking status, chronic obstructive 
pulmonary disease, gender and use of angiotensin converting enzyme inhibitors/angiotensin 
receptor blockers. External validation has to date been performed in the Swedish Heart 
Failure Registry covering 51 043 patients, indicating modest predictive accuracy for lower 
and higher risk patients, but overall confirming the risk score’s discriminatory power (Sartipy 
et al., 2014).  
Although not yet externally validated, the HF-ACTION prediction model includes HRQoL as 
a prognostic factor for hospitalisation or death (O'Connor et al., 2012). The model was 
derived in a sample of 2331 ambulatory patients with LVEF≤35% and NYHA classes II-IV 
who received current evidence-based treatment (of note, this may not be the case in some of 
the studies part of MAGGIC, see Sartipy et al., 2014). KCCQ symptom stability, indicating 
no symptoms or no change in symptoms over the last two weeks, was the second most 
important predictor in the model. Interestingly, change in either direction increased the risk of 
a negative outcome compared to symptom stability, with a hazard ratio of 1.91 (95% CI: 
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1.62–2.27) for worsened symptoms and a hazard ratio of 1.26 (95% CI: 1.11–1.43) for 
improved symptoms (O'Connor et al., 2012).  
2.3 REVIEW OF THE LITERATURE 
A focused literature review was performed for each of the relevant subtopics covered by this 
thesis. The selection was based on papers with a primary focus on the research topic of 
interest. The search was performed in PubMed and considered publications from the year 
2000 onwards. The following sections present selected findings from studies deemed 
interesting and relevant.  
2.3.1 Health-related quality of life and utilities in atrial fibrillation 
Many of the studies on factors influencing HRQoL in AF have been part of randomised 
controlled trials that have investigated different treatment strategies, in particular rate vs. 
rhythm control. While a range of different HRQoL instruments have been used in AF overall, 
most of these studies have used generic HRQoL instruments, in particular the SF-36 or 
abbreviated versions.  
Table 6 summarises key information from studies on drivers of HRQoL in AF. The studies 
have been selected to provide information from samples with more than 100 patients, and 
because they investigated a range of possible HRQoL drivers. The two largest studies have 
been performed in North America and the UK, respectively. Reynolds and colleagues 
(Reynolds et al., 2006) reported from a prospective observational registry of 963 patients with 
new onset AF, using the SF-12. Roalfe and colleagues (Roalfe et al., 2012) used both the EQ-
5D and SF-36 in an aged AF population of 1762 patients who were followed for stroke 
prevention in primary care.  
Variables that previously have been identified as independent determinants of HRQoL 
include gender, age, disease duration, AF symptoms, LVEF, NYHA class, valvular heart 
disease, depression, anxiety, degree of medication use (including beta-blockers, 
antiarrhythmic drugs), disability, comorbidities (including diabetes, hypertension, chronic 
obstructive pulmonary disease) and, where information over time was available, adverse 
events during follow-up. Type of AF (paroxysmal, persistent or permanent) has only been 
shown to be significant in some studies, which may partly be due to the specific populations 
and research questions. In general, randomised controlled trials comparing rhythm vs. rate 
control (e.g. AFFIRM, PIAF, RACE) have not shown any significant difference in overall 
HRQoL improvement with treatment between the types of therapy measured using the 
generic SF-36 instrument, although some differences between individual domains have been 
observed. It has been noted that this could be either due to lack of treatment effect in terms of 
health status, or insufficient sensitivity of the SF-36 to capture any smaller changes seen with 
pharmacological treatment (Coyne et al., 2005; Spertus et al., 2011).  
Apart from the utility functions in Paper I, health state utilities have only been published for 
selected disease states in AF. Based on an observational registry of new onset AF (Reynolds, 
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Morais & Zimetbaum, 2010), utilities derived from the SF-6D were compared between 
patients with and without hospitalisations during the first year. Patients not hospitalised had a 
mean utility of 0.81, compared to 0.77 for patients hospitalised for any cause (p<0.01). This 
relationship was confirmed when using a mixed linear regression model for the full 2.5-year 
follow-up period. Recently, a cross-sectional multinational survey of about 10 000 patients 
with AF (Steg et al., 2012) reported utilities based on the EQ-5D for AF control (defined as 
being in sinus rhythm or having AF with a resting ventricular rate ≤80 beats per minute). 
Controlled patients had a median utility score of 0.78 compared to 0.73 for uncontrolled 
patients (p<0.001). 
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Table 6: Selected studies on HRQoL drivers in AF 
Publication Country Setting Study design Sample 
size 
Patient characteristics at 
baseline 
HRQoL 
measure 
Main results 
Dorian et 
al., 2002 
Canada Clinical 
centres 
Prospective sub-study 
of RCT evaluating 
AADs (CTAF) 
294 Paroxysmal or persistent AF 
Mean age 65 years 
89% had LVEF>50% 
NYHA class I-II 
SF-36 Correlates of SF-36: age, gender, NYHA class 
Hagens et 
al., 2004a 
The 
Netherlands 
Clinical 
centres 
Sub-study of RCT on 
rate control vs. 
cardioversion 
(RACE) 
352 Persistent AF 
Mean age 68 years 
NYHA class I-III 
SF-36 Baseline correlates: gender, age, AF duration, AF 
symptoms, NYHA class, fractional shortening 
Determinants of change in HRQoL at study end (24 or 
36 months): age, AF symptoms, AF duration, sinus 
rhythm at end of follow-up 
Reynolds et 
al., 2006 
US, Canada Clinical 
centres 
Observational 
registry 
963 New onset AF 
Mean age 66 years 
 
SF-12 Physical and/or mental summary scores over 12 months 
driven by: NYHA class, gender, age, valve disease, prior 
MI, hypertension, initial AAD, initial warfarin, COPD, 
asthma, diabetes, hemiplegia, CTD 
Peinado et 
al., 2010 
Spain Routine 
clinical 
practice 
Prospective 
observational study 
341 Paroxysmal, persistent or 
permanent AF 
Mean age 60 years 
12% LV systolic dysfunction 
NYHA class I-IV 
AF-QoL  Total HRQoL score influenced by: NYHA class, number 
of emergency room visits during last year 
AF type only significant in psychological dimension 
Groenveld 
et al., 2011 
The 
Netherlands 
Clinical 
centres 
Sub-study of RCT on 
rate control strategies 
(RACE II) 
437 Permanent AF 
Mean age 68 years 
Mean LVEF 53% 
NYHA class I-III 
SF-36 Baseline correlates: gender, AF symptoms, diabetes 
Determinants of change in HRQoL at study end (2-3 
years): age, gender, AF symptoms, LVEF, septum 
thickness, diabetes, beta-blockers, HF hospitalisation, 
major bleeding, arrhythmic events during study 
Roalfe et 
al., 2012 
UK Primary 
care 
RCT of stroke 
prevention (BAFTA)
1762 Mean age 82 years EQ-5D, 
SF-12
HRQoL scores independently associated with gender, 
greater medication use and disability (Rankin scale) 
Akintade et 
al., 2013 
US Hospital 
clinics 
Cross-sectional 
observational study 
150 Paroxysmal, persistent or 
permanent AF; AFL 
Mean age 66 years 
Mean LVEF 48% 
SF-36 HRQoL summary scores determined by gender, 
depression, anxiety, AFL, permanent AF 
Notes: AAD=antiarrhythmic drug, AF=atrial fibrillation, AFL=atrial flutter, AF-QoL=Atrial Fibrillation-Quality of Life, BAFTA=Birmingham Atrial Fibrillation Treatment of the Aged, 
COPD=chronic obstructive pulmonary disease, CTAF=Canadian Trial of Atrial Fibrillation, CTD=connective tissue disease, HF=heart failure, HRQoL=health-related quality of life, 
LVEF=left ventricular ejection fraction, MI=myocardial infarction, NYHA=New York Heart Association, RACE=RAte Control versus Electrical cardioversion, RACE II=RAte Control 
Efficacy in permanent atrial fibrillation: A comparison between lenient and strict rate control II, RCT=randomised controlled trial  
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2.3.2 Economic evaluations in atrial fibrillation and the impact of utilities 
Table 7 summarises key information from selected cost-effectiveness evaluations of 
pharmacological therapies in AF. Studies investigating treatments for stroke prevention have 
been excluded. With the exception of the study by Marshall and colleagues (Marshall et al., 
2004), only studies reporting ICERs have been listed.  
AFFIRM and RACE were two major trials investigating rhythm vs. rate control in recurrent 
and persistent AF, respectively, both of which showed non-inferiority of rate control in terms 
of survival. In AFFIRM (Wyse et al., 2002), rate control therapy was associated with a 
significantly lower risk of hospitalisation and selected adverse events. In RACE (Van Gelder 
et al., 2002), the primary endpoint comprised cardiovascular morbidity and mortality, with 
the majority of endpoints occurring numerically more frequently with rhythm control. 
Reflecting these clinical results, rate control has also been shown to be cost-saving or 
dominant in subsequent cost-effectiveness analyses.  
Ablation has been compared to antiarrhythmic therapy in several studies. It is interesting to 
note the different methods used for utilities in these evaluations. Data were based on a 
combination of relatively different sources and assumptions, reflecting the lack of utility data 
in a comprehensive sample of AF patients at the time. As pointed out by McKenna and 
colleagues (McKenna et al., 2009), the necessity to use different sources introduced 
significant uncertainty around this model parameter.  
Most recently, a number of cost-effectiveness evaluations have been performed for 
dronedarone to support reimbursement applications in different markets. They have used 
different comparators and modelling frameworks, which in particular has informed the choice 
of data source for event rates (trial-based or from indirect comparisons). In terms of utilities, 
these studies have used values derived from the Euro Heart Survey (Paper I).  
Drivers of cost-effectiveness results are often related to the risk of events with or without 
treatment and the associated benefits in terms of costs or utility gains. In the study by 
McKenna and colleagues (McKenna et al., 2009), results were sensitive to assumptions 
around utilities assigned to health states and in particular the duration of HRQoL benefits 
following treatment. In the study by Reynolds and colleagues (Reynolds et al., 2009), results 
were most influenced by relative utility weights of different health states following therapy, 
cost of ablation and the modelling time horizon. Treatment duration was found to be a key 
driver in both models comparing dronedarone vs. standard of care (Akerborg et al., 2012; 
Reynolds et al., 2013). In the models comparing dronedarone against other antiarrhythmic 
drugs, results were most sensitive to assumptions around mortality benefits of and the 
incremental survival benefit with dronedarone (McKenna et al., 2012; Nilsson et al., 2013).  
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Table 7: Selected cost-effectiveness evaluations of pharmacological interventions in AF (not including stroke prevention) 
Publication Country 
(costing) 
Intervention Patient population Study type Time horizon 
and perspective 
Outcome measures 
and utility sources 
Main results (base case) 
Rhythm vs. rate control       
Hagens et 
al., 2004b 
The 
Netherlands 
Rate control drugs vs. 
rhythm control 
(electrical 
cardioversion and 
AADs) 
Patients with 
persistent AF or AFL 
as in RACE 
Prospective sub-study of 
RACE; cost-
minimisation and cost-
effectiveness analysis 
Mean follow-up 
2.3 years 
Societal 
Event avoided 
(cardiovascular 
morbidity and 
mortality) 
Rate control:  
Cost savings €898 per 
patient 
Cost savings per event 
avoided €24944 
Marshall et 
al., 2004 
US AADs vs. rate control 
drugs 
Patients similar to 
those in AFFIRM 
(mostly recurrent AF) 
Retrospective economic 
evaluation based on 
AFFIRM 
Mean follow-up 
3.5 years 
Third-party payer 
Survival (LYG) 
 
Rate control:  
Mean survival gain 0.08 
years 
Cost savings $5077 per 
patient
Perez et al., 
2011 
US Rate vs. rhythm 
control 
Patients with 
persistent or 
paroxysmal AF with 
heart failure 
Markov model Lifetime 
Third-party payer 
QALYs 
Published index scores 
for chronic conditions 
Rate control dominant 
Ablation vs. pharmacological treatment     
Chan et al., 
2006 
US Left atrial catheter 
ablation vs. rate 
control drugs or 
amiodarone 
Hypothetical cohort 
of AF patients at low-
moderate risk of 
stroke 
Markov model Lifetime 
Societal 
QALYs  
Utilities largely based 
on assumptions 
ICER range $28700-
$98900/QALY depending 
on stroke risk and age 
Amiodarone dominated by 
rate control 
Reynolds et 
al., 2009 
US Radiofrequency 
catheter ablation vs. 
AAD 
Drug-refractory 
paroxysmal AF 
Markov model 5 years 
Societal 
QALYs 
Utilities from 
FRACTAL registry, 
prospective cohort and 
A4 trial 
ICER $51431/QALY 
McKenna et 
al., 2009 
UK Radiofrequency 
catheter ablation vs. 
AAD (amiodarone) 
Paroxysmal AF Decision analytic model 
based on Bayesian 
evidence synthesis 
Lifetime 
Health service  
QALYs 
Utilities based on 
decrements from UK 
general population 
ICER range £7763-
£7910/QALY depending 
on stroke risk  
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Dronedarone vs. other drugs      
Akerborg et 
al., 2012 
Canada, 
Italy, 
Sweden, 
Switzerland 
Dronedarone on top 
of SOC vs. SOC 
alone 
Paroxysmal or 
persistent AF or AFL 
Microsimulation model, 
mainly based on patient-
level data from 
ATHENA 
Lifetime, 
treatment 21 
months 
Payer (NHS) 
Survival (LYG) 
QALYs 
Utilities based on Euro 
Heart Survey 
ICER range €5828-
€14970/QALY across 
countries 
McKenna et 
al., 2012 
UK Dronedarone vs. 
SOC, amiodarone, 
sotalol or class 1c 
agents 
Paroxysmal or 
persistent AF or AFL 
Discrete event  model, 
based on data from 4 
dronedarone trials and 
indirect comparisons 
Lifetime 
NHS and PSS 
QALYs  
Utilities based on Euro 
Heart Survey 
ICER range £1692-
£18955/QALY across 
different patient 
populations and 
comparators 
Reynolds et 
al., 2013 
US Dronedarone on top 
of SOC vs. SOC 
alone 
Paroxysmal or 
persistent AF or AFL 
Microsimulation model, 
mainly based on patient-
level data from 
ATHENA 
Lifetime, 
treatment 21 
months 
Payer  
Survival (LYG) 
QALYs 
Utilities based on Euro 
Heart Survey 
ICER $19520/QALY 
Nilsson et 
al., 2013 
Canada, 
Italy, 
Sweden, 
Switzerland 
Dronedarone on top 
of SOC vs. 
amiodarone, sotalol 
or flecainide on top 
of SOC 
Paroxysmal or 
persistent AF or AFL 
Microsimulation model, 
mainly based on patient-
level data from 
ATHENA 
Lifetime 
Payer (NHS) 
Survival (LYG) 
QALYs 
Utilities based on Euro 
Heart Survey 
ICER range €2290-
€6140/QALY across 
countries and comparators 
Notes: A4=Catheter Ablation versus AntiArrhythmic drugs for Atrial fibrillation, AAD=antiarrhythmic drug, AF=atrial fibrillation, AFFIRM=Atrial Fibrillation Follow-up Investigation of 
Rhythm Management, AFL=atrial flutter, ATHENA=A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of 
cardiovascular Hospitalization or death from any cause in PatiENts with Atrial fibrillation/atrial flutter, ICER=incremental cost-effectiveness ratio, LYG=life years gained, NHS=national 
health service, PSS=personal social services, QALY=quality-adjusted life year, RACE=RAte Control versus Electrical cardioversion, SOC=standard of care  
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2.3.3 Health-related quality of life and utilities in chronic heart failure 
Determinants of HRQoL in HF have been investigated in a number of studies using both 
generic and disease-specific instruments, covering patients from hospital and outpatient 
settings. The largest samples have been based on the CARE-HF trial (Calvert, Freemantle & 
Cleland, 2005) and the outpatient INCA study (de Rivas et al., 2008), including 813 and 2161 
patients, respectively. These two studies, as well as a study in 293 patients with emergency 
admissions (Holland et al., 2010) and a randomised controlled trial on iron deficiency 
(Gutzwiller et al., 2013), have used the EQ-5D. Other commonly used HRQoL instruments 
include the SF-36, MLWHFQ and KCCQ.  
Variables that previously have been found to be independent determinants of HRQoL in CHF 
include: age, gender, NYHA class, LVEF, comorbidities (in particular chronic obstructive 
pulmonary disease and diabetes), medical history, renal function, body mass index, functional 
measures, symptoms, medications (including aldosterone antagonists, antiarrhythmic drugs), 
depression and sociodemographic variables.  
Table 8 summarises key information from studies on drivers of HRQoL in CHF. The studies 
have been selected to provide information from samples with more than 200 patients, and 
with the goal of covering a broad range of possible HRQoL drivers.  
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Table 8: Selected studies on HRQoL drivers in CHF 
Publication Country Setting Study design Sample 
size 
Patient characteristics 
at baseline 
HRQoL measure Main results 
Calvert et al., 
2005 
International Clinical 
centres 
RCT on cardiac 
resynchronisation 
therapy (CARE-HF) 
813 Mean age 65 years 
Mean LVEF 26% 
NYHA III-IV 
EQ-5D, MLWHFQ HRQoL scores significantly related to gender and 
NYHA class 
Lee et al., 
2005 
Hong Kong Hospital 
admissions 
Cross-sectional 227 Mean age 77 years 
NYHA class I-IV
Chronic Heart Failure 
Questionnaire
HRQoL score significantly correlated with HADS 
score, health perception, NYHA, educational level
Gott et al., 
2006 
UK General 
practice 
Cross-sectional 
survey 
542 Age >60 years 
NYHA class I-IV 
SF-36, KCCQ HRQoL predictors: gender, NYHA class, depression, 
socioeconomic group, age, number of comorbidities 
Franzen et 
al., 2007 
Sweden Hospital 
register 
Cross-sectional 
survey 
357 Mean age 79 years 
Self-rated NYHA I-IV 
SF-12, MLWHFQ Predictors SF-12 physical component summary: 
NYHA, age, gender, diabetes, respiratory diseases 
de Rivas et 
al., 2008 
Spain Outpatient 
clinics 
Cross-sectional 2161 Mean age 71 years 
Mean LVEF 48% 
NYHA class I-IV 
EQ-5D, MLWHFQ Drivers EQ-5D VAS: age, gender, NYHA, LVEF, 
renal dysfunction, haemoglobin, COPD, diabetes, 
follow-up in primary care; MLWHFQ: age, gender, 
NYHA, LVEF, renal dysfunction, serum potassium, 
COPD, diabetes, hypertension, valve disease 
Faller et al., 
2009 
Germany Out-
patients 
Prospective cohort 
study 
206 Mean age 64 years 
52% systolic HF 
NYHA I-IV 
KCCQ, Patient 
Health Questionnaire 
depression module 
Depression influenced psychological and physical 
KCCQ domains; NYHA class influenced only physical 
domain 
de Leon et al., 
2009 
US Out- and 
inpatient 
screening 
RCT on behavioural 
intervention  
695 Mean age 63 years 
24% diastolic HF 
NYHA class II-III 
SF-36 Physical 
Functioning, QoL 
Index-Cardiac Ver. 
SF-36 scores associated with: age, race, education, 
number of comorbidities, NYHA class, depression, HF 
symptoms and functional characteristics 
Holland et al., 
2010 
UK Emergency 
hospitali-
sation 
Observational cohort 
part of RCT 
(pharmacist advice) 
293 Mean age 77 years 
NYHA class I-IV (self-
assigned) 
EQ-5D, MLWHFQ Significant predictors of MLWHFQ at 6 months: self-
assigned NYHA class, 3-month MLWHFQ scores, 
antiarrhythmic drug use, BMI 
Peters-Klimm 
et al., 2010 
Germany Primary 
care 
Cross-sectional 318 Mean age 69 years 
Mean LVEF 35% 
NYHA class I-IV 
SF-36, KCCQ Determinants of (some) HRQoL scales: practice list 
size, age, social class, NYHA class, COPD, history of 
CABG surgery, multimorbidity, aldosterone 
antagonist, self-care, depression 
Gutzwiller et 
al., 2013 
International Clinical 
centres 
RCT on iron 
deficiency  
459 Mean age 68 years 
Mean LVEF 32% 
NYHA class II-III 
EQ-5D, KCCQ EQ-5D VAS and KCCQ at 24 weeks significantly 
associated with: treatment group, NYHA class, eGFR, 
stroke, functional test, country of residence 
Notes: BMI=body mass index, CABG=coronary artery bypass grafting, CARE-HF=CArdiac REsynchronisation in Heart Failure, COPD=chronic obstructive pulmonary disease, eGFR=estimated 
glomerular filtration rate, HADS=Hospital Anxiety and Depression Scale, HF=heart failure, HRQoL=health-related quality of life, KCCQ=Kansas City Cardiomyopathy Questionnaire, 
LVEF=left ventricular ejection fraction, MI=myocardial infarction, MLWHFQ=Minnesota Living With Heart Failure questionnaire, NYHA=New York Heart Association, RCT=randomised 
controlled trial  
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To date, the only published study to have generated utility functions for HF patients that can 
be used in economic evaluations is based on a subsample of 1395 patients from the 
EPHESUS trial (Gohler et al., 2009). HRQoL was modelled with the EQ-5D at several time 
points using NYHA class and cardiovascular rehospitalisations as major independent 
variables, also adjusting for age, gender and cardiovascular comorbidities.  
In addition, six further studies have derived utilities for relevant clinical subgroups, mostly by 
NYHA class (see Table 9). Three studies have used the direct elicitation techniques time-
trade off and standard gamble, while four studies have used indirect techniques deriving 
utilities based on the EQ-5D, SF-6D and HUI-3. As the samples differ across studies, with 
settings ranging from primary and specialist outpatient care, inpatient care to even the general 
population, the different utilities by NYHA class are most likely a reflection of the underlying 
sample characteristics in terms of setting, age and LVEF. Interestingly, the general population 
sample yielded some of the highest utility estimates (Nichol et al., 2004).  
In one of the first studies focusing on patient preferences for survival compared to 
improvements in symptoms, Lewis and colleagues (Lewis et al., 2001) used both the standard 
gamble and time trade-off techniques in a sample of advanced HF patients. They found a 
good correlation between the two preference measures. Physiologic measures of disease 
severity, specifically NYHA class, peak oxygen consumption and jugular venous pressure, 
were closely correlated with utility scores, while age, gender, duration of HF and LVEF were 
not. By collecting HRQoL information using the MLWHFQ, the study also highlighted the 
fact that HRQoL and utilities are two distinct concepts measuring overlapping, yet separate 
constructs. So although MLWHFQ scores and utilities showed modest correlation, the 
HRQoL scores were distributed evenly over the whole spectrum of possible answers, while 
patient preferences were strongly weighted towards the highest or lowest possible utility 
values (time-trade off scores). This suggests that the preferences reflect additional 
components apart from HRQoL or functional status that influence patients’ willingness to 
trade all or none of their remaining life for achieving full health (Lewis et al., 2001).  
More recently, Kontodimopoulos and colleagues (Kontodimopoulos et al., 2011) compared 
utilities derived from the EQ-5D and SF-6D in CHF patients undergoing elective cardiac 
surgery. Disease severity was measured with the Duke Activity Status Index rather than 
NYHA class. A strong correlation of EQ-5D and SF-6D values was seen, but agreement was 
poor in particular for subgroups with low functional capacity. The authors derived a cross-
over point between EQ-5D and SF-6D utilities at 0.722, above which utility scores would be 
higher with the EQ-5D than the SF-6D, and below which the opposite would hold. Of note, 
the EQ-5D VAS was not able to differentiate between patient groups in terms of disease 
characteristics. In addition to the utilities by level of LVEF, the authors also reported utilities 
by other patient categories, e.g. gender (women lower than men) and age (no clear trend) 
(Kontodimopoulos et al., 2011).  
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Table 9: Previous studies presenting utility weights for CHF 
Publication Country Setting Sample 
size 
Patient characteristics at 
baseline 
Utility measure Utility weights 
Lewis et al., 2001 US Hospital patients 99 Mean age 52 years 
Mean LVEF 24% 
NYHA class I-IV 
TTO, SG Estimates based on graph: 
NYHA I: 1.0 (TTO), 0.99 (SG) 
NYHA II: 0.9 (TTO), 0.8 (SG) 
NYHA III: 0.65 (TTO), 0.65 (SG) 
NYHA IV: 0.3 (TTO), 0.35 (SG)
Nichol et al., 2004 Canada Convenience sample from 
general population 
66 Mean age 49 years SG NYHA II: 0.82 
NYHA III: 0.72 
NYHA IV: 0.58
Alehagen et al., 
2008 
Sweden Patients from primary care 
clinics 
323 Mean age 72 years 
LVEF<30%: 1%, 30-39%: 
9%, 40-49%: 14%, ≥50%: 
76% 
Self-assessed NYHA class I-
IV 
TTO Self-assessed NYHA  
NYHA I: 0.77 
NYHA II: 0.68 
NYHA III: 0.61 
NYHA IV: 0.50 (incl. NYHA IIIb, i.e. not able 
to walk >200m) 
Miller et al., 2009 US Community sample, part 
of disease management 
trial 
751 Mean age 70 years 
Mean LVEF 35% 
NYHA class I-IV 
SF-6D NYHA I: 0.75 
NYHA II: 0.64 
NYHA III and IV: 0.58 
Gohler et al., 2009 International  RCT (EPHESUS) of 
eplerenone in post-acute 
MI patients; HRQoL sub-
study 
1395 Mean age 64 years 
Mean LVEF 32% 
NYHA class I-IV 
EQ-5D Univariate associations with utility: 
NYHA I: 0.855 
NYHA II: 0.771 
NYHA III: 0.673 
NYHA IV: 0.532 
Pressler et al., 
2011 
US Convenience sample of 
CHF patients from primary 
care and heart clinics 
210 Mean age 57 years 
NYHA class I-IV 
HUI-3 NYHA I: 0.76 
NYHA II: 0.56 
NYHA III: 0.35 
NYHA IV: 0.24 
Kontodimopoulos 
et al., 2011 
Greece Hospital admissions for 
elective cardiac surgery 
251 Mean age 66 years 
Mean LVEF 52% 
EQ-5D, SF-6D Utilities by level of LVEF: 
<50%: 0.621 (EQ-5D), 0.677 (SF-6D) 
50-59%: 0.712 (EQ-5D), 0.702 (SF-6D) 
>60%: 0.755 (EQ-5D), 0.743 (SF-6D) 
Notes: EPHESUS=Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival, HRQoL=health-related quality of life, HUI-3=Health Utilities Index Mark-3, 
LVEF=left ventricular ejection fraction, MI=myocardial infarction, NYHA=New York Heart Association, RCT=randomised controlled trial, SG=standard gamble, TTO=time trade-off  
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2.3.4 Impact of health-related quality of life on clinical outcomes in chronic 
heart failure 
Given the high mortality and morbidity in CHF, considerable research efforts have been 
invested to understand prognostic factors in this population. The role of HRQoL as an 
independent predictor of hospitalisations and mortality has been studied in different age 
groups, stages of CHF and settings, including primary care, specialist outpatient care, 
following hospitalisation and in randomised trials. Several disease-specific and generic 
HRQoL measurements have been used, including the MLWHFQ, KCCQ, SF-36 and health 
status questions. The follow-up period in most previous studies has been limited to between 
six months and five years. Only few studies with a follow-up of over five years have 
investigated HRQoL and mortality (Johansson et al., 2008; Lupon et al., 2013; Zuluaga et al., 
2010), and there is a lack of long-term results concerning HRQoL and readmissions. 
Previously identified predictors of mortality (all or cardiovascular causes) have included 
HRQoL, age, gender, NYHA class, disease history/duration, LVEF, comorbidities, clinical 
measures such as renal function and type of drug treatment (beta-blockers, angiotensin 
converting enzyme inhibitors, diuretics). Predictors of hospitalisations (all or cardiovascular 
causes) have included HRQoL, age, gender, NYHA class, comorbidities and beta-blockers.  
Table 10 summarises studies relevant for the context of long-term prognosis, usually with 
sample sizes of at least 200 patients to allow for the high mortality rate (except for selected 
studies with HRQoL measures of specific interest, e.g. utilities based on the standard gamble 
technique or EQ-5D).  
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 Table 10: Selected studies on the role of HRQoL in HF prognosis with follow-up of more than one year 
Publication Country Setting Sample 
size 
Patient characteristics 
at baseline 
HRQoL measure Outcomes 
measure 
Duration of 
follow-up 
Main results 
Stull et al., 
2001 
Inter-
national  
RCT of enalapril 
(SOLVD)  
3884 (in 
multi-
variate 
analyses) 
Mean age 59 years 
LVEF ≤35%, mean 
27% 
NYHA class I-III 
Battery of self-
reported QoL 
questions (51 items) 
HF-related 
hospitalisation 
Mean 3 
years; up to 
5 years 
HRQoL independent predictor in 
multivariate analyses for all age 
groups, with different clinical 
predictors  
Soto et al., 
2004 
Inter-
national  
RCT (EPHESUS) 
of eplerenone in 
post-acute MI 
patients; HRQoL 
sub-study 
1516 Mean age 64 years 
Mean LVEF 33% 
NYHA class I-IV 
KCCQ Combined 
endpoint of 1-year 
cardiovascular 
death or 
hospitalisation 
Mean 16 
months 
Independent predictors combined 
endpoint: age, COPD, diabetes, prior 
MI, prior HF, post-MI LVEF, beta-
blockers, KCCQ summary score 
Mejhert et 
al., 2006 
Sweden Patients 
hospitalised for HF 
208 Mean age 76 years 
Mean LVEF 34% 
NYHA class II-IV 
NHP All-cause 
mortality and 
rehospitalisation 
Mean 3.1 
years 
Rehospitalisation: NHP total score 
only significant predictor; 
Mortality: age, gender, BNP, 
creatinine, LV systolic function 
independent predictors 
Sullivan et 
al., 2007 
US Heart failure/ pre-
transplant clinic 
142 Mean age 53 years 
Mean LVEF 27% 
Mean NYHA class 2.7 
SF-36 (health status 
question), KCCQ 
summary score, 
feeling 
thermometer, SG 
Combined 
endpoint of heart 
transplant or 
death 
Mean 3 
years 
Standard gamble only significant 
health status measure when 
controlling for significant clinical 
variables 
Faller et al., 
2007 
Germany Outpatients at 
university centres 
231 Mean age 64 years 
Mean EF 44% 
NYHA class I-IV 
SF-36, KCCQ, 
Patient Health 
Questionnaire 
(depression) 
All-cause 
mortality 
Median 2.7 
years 
Significant predictors in multivariate 
models: SF-36 mental score - LVEF, 
NYHA class; KCCQ - age, NYHA 
class 
Subramanian 
et al., 2007 
US Veteran Affairs 
outpatients 
494 Mean age 68 years 
Left ventricular 
dysfunction 
NYHA class I-IV 
 
SF-36, KCCQ, 
McMaster Chronic 
Heart failure 
Questionnaire 
All-cause 
mortality 
5 years Independent predictors: age, COPD, 
hypertension, hyperlipidaemia, other 
comorbidities, number of previous 
hospitalisations, beta-blockers, 
diuretics, creatinine, sodium, heart 
rate, KCCQ change over time score 
Johansson et 
al., 2008 
Sweden Patients treated in 
primary care 
448 Mean age 73 years 
12% with LVEF<40% 
NYHA class I-III 
Health status 
question from SF-
36 
All-cause and 
cardiovascular 
mortality 
10 years Independent predictors 
cardiovascular mortality: global 
health perception at baseline, age, 
gender, NYHA, diabetes, LVEF, 
BNP
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Iqbal et al., 
2010 
UK HF patients 
discharged from 
cardiology wards or 
outpatient clinics 
179 Mean age 71 years 
NYHA class I-IV 
EQ-5D, MLWHFQ All-cause 
mortality, all-
cause and HF 
rehospitalisation 
Mean 
follow-up 
3.3 years 
Survival only predicted by previous 
HF hospitalisation and lack of beta-
blockers in multivariate analyses; HF 
rehospitalisation by MLWHFQ score 
and beta-blockers 
O'Loughlin et 
al., 2010 
Ireland Survivors of NYHA 
class IV hospital 
admission enrolled 
in disease 
management 
programme 
225 Mean age 69 years 
78% had LVEF<45% 
87% had NYHA class 
I-II 
MLWHFQ All-cause 
mortality, all-
cause emergency 
admission 
Mean 18 
months 
Predictors multivariate models:  
Mortality - HRQoL, HRQoL*age 
interaction, age, gender, creatinine, 
systolic blood pressure; 
Emergency admission - HRQoL, 
HRQoL*age, age, gender, NYHA 
class, cancer 
Zuluaga et 
al., 2010 
Spain Patients admitted 
for emergency 
hospitalisation 
416 Mean age 77 years 
45% had LVEF≤45% 
34% had NYHA class 
III-IV 
SF-36, MLWHFQ All-cause 
mortality 
7 years Independent predictors: HRQoL, age, 
ischaemic aetiology, NYHA class, 
comorbidity index, COPD, creatinine, 
ACEI, beta-blockers, recent HF 
hospitalisation 
Chamberlain 
et al., 2013 
US Community sample 
covering in- and 
outpatients, HFPEF 
and HFREF 
352 Mean age 73 years  SF-12, physical 
component score, 
self-rated general 
health 
All-cause 
mortality 
Mean 2.3 
years 
Self-rated health and functional 
exercise capacity independently 
predicted mortality in adjusted Cox 
models 
Hoekstra et 
al., 2013 
The 
Nether-
lands 
Patients 
hospitalised for HF 
661 Mean age 71 years 
Mean LVEF 34% 
NYHA class II-IV 
Ladder of life, 
RAND-36, 
MLWHFQ 
All-cause 
mortality 
3 years In model adjusted for demographic 
and clinical variables, only physical 
functioning and general health 
dimensions of RAND36 significant 
Lupon et al., 
2013 
Spain Outpatients referred 
to HF university 
hospital clinic  
1151 Median age 69 years 
Median LVEF 31% 
NYHA class I-IV 
MLWHFQ All-cause 
mortality 
Up to 6 
years 
Predictors multivariate model: 
HRQoL, age, gender, HF duration, 
NYHA class, diabetes, anaemia, 
peripheral vascular disease, beta-
blockers, ACEI/ARB 
Notes: ACEI=angiotensin-converting-enzyme inhibitor, ARB= angiotensin II receptor blocker, BMI=body mass index, BNP=brain natriuretic peptide, COPD=chronic obstructive pulmonary 
disease, eGFR=estimated glomerular filtration rate, EPHESUS=Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival, HFPEF=heart failure with preserved 
ejection fraction, HFREF=heart failure with reduced ejection fraction, HRQoL=health-related quality of life, KCCQ=Kansas City Cardiomyopathy Questionnaire, LVEF=left ventricular 
ejection fraction, MI=myocardial infarction, MLWHFQ=Minnesota Living With Heart Failure Questionnaire, NHP=Nottingham Health Profile, NYHA=New York Heart Association, 
SG=standard gamble, SOLVD= Studies of Left Ventricular Dysfunction 
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2.3.5 Identified knowledge gaps 
Based on the focused literature review on the different subtopics, knowledge gaps could be 
identified in the following areas: 
 Utilities in AF and driving factors based on a comprehensive sample of patients 
covering relevant clinical variables, including AF type (first detected, paroxysmal, 
persistent and permanent) and adverse events; 
 Cost-effectiveness analyses evaluating AF treatments using utilities from a large 
comprehensive patient sample; 
 Utilities in CHF and driving factors based on a comprehensive sample of patients 
from clinical practice covering different treatment settings and levels of LVEF;  
 Prognostic value of HRQoL in CHF for death over a timeframe of more than six years 
and for rehospitalisations over more than three years.  
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3 AIMS OF THE THESIS 
The overarching aim of this thesis is to enhance the knowledge on what drives HRQoL and 
utilities in patients with AF and CHF, and how these in turn influence clinical and economic 
outcomes. Specifically, the following four research questions have been investigated in the 
included papers: 
 What factors drive utility in patients with AF at different time points? (Paper I) 
 What is the cost-effectiveness of a new treatment for AF, given data from a 
morbidity/mortality trial and derived utility weights? (Paper II) 
 What factors drive utility in patients with CHF and what statistical model is most 
suited for the data? (Paper III)  
 What is the impact of HRQoL on long-term morbidity and mortality in patients 
hospitalised with systolic CHF? (Paper IV)  
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4 MATERIALS AND METHODS 
4.1 MATERIALS 
4.1.1 The Euro Heart Survey on Atrial Fibrillation 
The Euro Heart Survey on AF was an observational study enrolling 5333 patients from 
cardiology clinics across 35 European countries during 2003 and 2004 (Nieuwlaat et al., 
2005). Inclusion criteria were age ≥18 years and AF on electrocardiogram or Holter recording 
at the enrolment visit or during the preceding 12 months. The overarching objective of the 
study was to describe and compare clinical practice against guidelines. A range of 
demographic, clinical, treatment and functional variables were collected at baseline, including 
the EQ-5D for measuring HRQoL. After one year, information was collected on AF type, 
HRQoL, adverse events and interventions during follow-up. Figure 11 summarises 
information about the patient sample, key variables and outcomes studied in Paper I.  
Figure 11: Study flow chart describing patient sample, key variables and outcomes of 
interest – Paper I (Euro Heart Survey on Atrial Fibrillation) 
 
Notes: AF=atrial fibrillation, HRQoL=health-related quality of life 
At baseline, 5050 patients (corresponding to 95%) had complete information on the EQ-5D, 
compared to 3045 (76% of surviving patients not lost to follow-up) at one year. Mean age at 
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baseline was 66 years, 58% were male. There was a relatively even distribution amongst AF 
types (first detected, paroxysmal, persistent and permanent); 70% of patients were 
experiencing symptoms. At follow-up, only 34% of patients were symptomatic; at the same 
time, there had been a shift towards permanent AF representing the most frequent AF type 
(41%).  
4.1.2 The ATHENA trial 
ATHENA (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of 
dronedarone 400mg bid for the prevention of cardiovascular Hospitalization or death from 
any cause in patiENts with Atrial fibrillation/atrial flutter) was the first clinical trial in AF to 
incorporate morbidity and mortality outcomes in its primary endpoint. It evaluated the effect 
of dronedarone, a new antiarrhythmic drug, against placebo on top of standard of care in 
patients with paroxysmal or persistent AF or atrial flutter, who were ≥75 years or ≥70 years 
with at least one cardiovascular risk factor. The study enrolled 4628 patients in 37 countries, 
who were followed for at least 12 months (Hohnloser et al., 2009). Figure 12 summarises 
information about the patient sample, key variables and outcomes studied in Paper II. The 
methods relevant to the trial-based cost-effectiveness analysis are detailed in Section 4.2.2.  
Figure 12: Study flow chart describing patient sample, key variables and outcomes of 
interest – Paper II (ATHENA within-trial analysis) 
 
Notes: AF=atrial fibrillation, BID=two times a day, CV=cardiovascular 
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At baseline, mean age in the trial population was 72 years. In the dronedarone arm, 51% were 
male, compared to 55% in the placebo arm. Hypertension was the most common comorbidity 
(86%), 60% had structural heart disease and 21% a history of CHF (Hohnloser et al., 2009).  
4.1.3 The Swedish Heart Failure Registry 
The Swedish Heart Failure registry was established in 2003 to describe CHF management in 
Swedish clinical practice, with the ultimate goal of improving the quality of care. Inclusion 
can occur at discharge from hospital (within one month) or following an outpatient visit. The 
majority of patients have been included from hospitals (93% of all 50 827 patients in 2012), 
with the rest stemming from primary care (Vasko, Jonsson & Dahlstrom, RiksSvikt, 2013). 
Information is collected on demographics, lifestyle factors, disease characteristics, 
diagnostics, laboratory measures, medications, CHF symptoms and HRQoL; the latter is 
measured with the EQ-5D. Follow-up occurs after one year through a questionnaire covering 
functional capacity, HRQoL and current medications. Figure 13 summarises information 
about the patient sample, key variables and outcomes studied in Paper III. 
Figure 13: Study flow chart describing patient sample, key variables and outcomes of 
interest – Paper III (Swedish Heart Failure Registry) 
 
Notes: CHF=chronic heart failure, DBP=diastolic blood pressure, HRQoL=health-related quality of life, 
LVEF=left ventricular ejection fraction, NYHA=New York Heart Association, SBP=systolic blood pressure 
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In the sample extracted until the end of 2010, 5334 patients had completed the EQ-5D at 
inclusion (14% of all patients), compared to 3495 of patients at 1-year follow-up (66% of 
those with EQ-5D at baseline). Mean age at inclusion was 73 years and 65% were male. The 
majority of patients were in NYHA classes II-III, and 17% had HFPEF. The low proportion 
of patients with complete HRQoL information at baseline is partly due to this information 
only being collected since 2008, and partly a reflection of a higher priority given to clinical 
information at the time of inclusion (which often coincides with a hospitalisation).   
4.1.4 The OPTIMAL study 
The Optimising congestive heart failure outpatient clinic project (OPTIMAL) was a 
randomised prospective study in patients ≥60 years hospitalised with systolic HF and NYHA 
class II-IV at Danderyd University Hospital in Stockholm, Sweden, during 1996-1999. The 
primary study endpoint was the impact of a nurse monitored management programme on 
HRQoL. A range of clinical parameters, echocardiographic variables and neurohormonal 
activation indices were collected at baseline, together with information on functional capacity 
and HRQoL, which was measured using the generic NHP instrument. Follow-up occurred 
through scheduled visits at 6, 12 and 18 months; long-term follow-up over 8-12 years was 
performed through medical records and administrative databases. Figure 14 summarises 
information about the patient sample, key variables and outcomes studied in Paper IV. 
Of the 208 patients included in the study, 177 had completed the NHP at baseline. Mean age 
was 76 years and 56% were male. The vast majority were in NYHA classes II-III, mean 
LVEF was 34%. 
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Figure 14: Study flow chart describing patient sample, key variables and outcomes of 
interest – Paper IV (OPTIMAL) 
 
Notes: BNP=brain natriuretic peptide, CRP=C-reactive protein, DBP=diastolic blood pressure, 
HRQoL=health-related quality of life, LVEF=left ventricular ejection fraction, NHP=Nottingham Health 
Profile, NYHA=New York Heart Association, SBP=systolic blood pressure 
4.2 METHODS 
4.2.1 Regression analysis 
4.2.1.1 Modelling utility  
In Papers I and III, the key outcome variable of interest was utility derived from the EQ-5D; 
in Paper III, change in utility over one year was also analysed. Utilities are usually not 
normally distributed, as they tend to have a “spike” at the ceiling value, e.g. 1 for the EQ-5D 
when using the health state valuations from the UK general public. Moreover, they are 
bounded at the possible maximum and minimum values that can be obtained using the 
respective algorithm for converting health states to utilities. Therefore, linear regression using 
ordinary least squares (OLS) may not provide correct estimations for the significance of 
model parameters, as two important assumptions underlying OLS regression do not hold, 
namely that the outcome variable should be normally distributed and that the error terms 
should be normally distributed with mean zero and constant variance (homoscedasticity).  
A number of different techniques have been proposed and tested to address the statistical 
properties of utility data, yet there is no single method that has been shown to be generally 
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preferable to date. At the time of designing and conducting the analyses for Paper I, a method 
that had generated interest in the context of utility data was Powell’s censored least absolute 
deviations (CLAD) estimator (Powell, 1984). Its benefits are that it does not depend on 
distributional or homoscedasticity assumptions and is robust to censoring. However, this is 
achieved by modelling the median rather than the mean, which is a drawback for economic 
evaluations that inherently focus on mean values. In Paper I, we therefore used the CLAD 
method for deriving covariates that significantly impacted on utility through stepwise 
regression, and then used these variables in an OLS regression to obtain mean coefficients for 
prediction.  
The fact that CLAD (and Tobit) regression assumes that utilities are truncated at 1, i.e. that it 
conceptually would be possible to obtain health states that are better than perfect health, has 
subsequently been criticised from a theoretical standpoint and has also been shown to lead to 
bias in the mean estimates. Instead, OLS regression using robust standard errors or non-
parametric bootstrapping has been recommended as an unbiased estimator producing valid 
confidence intervals in sufficiently large samples (Pullenayegum et al., 2010). An important 
caveat is that the OLS model needs to be correctly specified, e.g. taking interaction terms into 
account and using suitable functional forms for model covariates, in particular checking for 
non-linearity (Kirkwood & Sterne, Blackwell Science, 2005; Pullenayegum, Wong & Childs, 
2013). Therefore, we chose to use OLS with robust standard errors as the main analytical 
approach in Paper III. The model selection was based on initial univariate and subsequent 
multivariate regressions. In addition, we performed a sensitivity analysis using two-part 
models, which have been proposed as an alternative method for utility data, as they are 
particularly suited for modelling the ceiling effect; a disadvantage is that they do not provide 
outputs that can be directly used for the calculation of means (Huang et al., 2008; 
Pullenayegum et al., 2010). We compared the model predictions for the two regression 
methods using within-sample validation, comparing accuracy on an aggregate and individual 
level as well as prediction ranges.   
For the analyses relating to change in utility over one year, this outcome variable is not 
associated with the same distributional issues as utility. In our samples for Paper III, the 
change in utility had a high kurtosis, but was otherwise relatively normally distributed. 
Therefore, we used OLS with robust standard errors to determine drivers of change.  
4.2.1.2 Time-to-event analyses 
In Paper IV, the key outcome variables were time to death and time to rehospitalisation, for 
all or cardiovascular causes. We used Cox proportional hazard regression to model the 
relationship between demographic, clinical and functional variables and the respective 
outcome of interest. Since the NHP instrument does not have a defined summary score, 
exploratory factor analysis was used to determine the groups (factors) consisting of HRQoL 
dimensions that explained most of the common variance (Fayers & Machin, John Wiley & 
Sons Ltd., 2007); as there is weak correlation between the derived factors, these could then be 
used as covariates in the Cox regression models. The proportional hazards assumption of the 
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Cox model, i.e. that the ratio of the hazards between different patient groups remains constant 
over time, was tested using Schoenfeld residuals.  
4.2.2 Cost-effectiveness analysis 
In Paper II, we performed a trial-based cost-effectiveness analysis of dronedarone vs. placebo 
on top of standard of care, using patient-level data from ATHENA. The analysis was based 
on a Canadian payer perspective, and different outcomes were assessed over the trial duration 
and extended to a lifetime horizon. We tested for heterogeneity across countries and 
differences in baseline utility. Sensitivity analyses were performed around different input 
parameters, including scenario and subgroup analyses to mirror label restrictions for 
dronedarone following later results from the PALLAS (Permanent Atrial Fibrillation 
Outcome Study Using Dronedarone on Top of Standard Therapy) trial. Uncertainty was 
presented using confidence intervals and cost-effectiveness acceptability curves for the 
different outcomes.  
Treatment-related resources were based on the case report forms, excluding protocol-driven 
costs such as regular laboratory tests. Thus, the types of resources covered the following: 
cardiovascular hospitalisations, hospitalisations due to treatment-related adverse events, 
outpatient examinations and procedures, study drug and concomitant medications. Costing 
was performed using standard public sources. In line with Canadian guidelines, we used a 
health care payer perspective, which does not cover costs due to lost productivity or other 
non-medical resources such as home help. Considering the relatively high mean age of 
patients with AF, both in general and particularly in ATHENA, costs due to lost productivity 
contribute with a comparatively small proportion to overall costs. For example, in an analysis 
based on the Euro Heart Survey on AF, work loss was found to account for 4-17% of total 
annual costs across the five countries contributing most patients (Ringborg et al., 2008). 
Mean age in these countries was 68 years, compared to 72 years in ATHENA, where 19% of 
patients were younger than 65 years (Hohnloser et al., 2009). In this light, the impact of 
perspective on total costs is smaller than for diseases affecting younger populations. 
Moreover, for dronedarone, the reduction of cardiovascular events and mortality seen with 
treatment could in a societal perspective also be expected to be reflected in reduced sick leave 
and reduced need for services outside the health care system. 
We evaluated three different outcome measures:  
 Number of events avoided: based on the primary efficacy endpoint in ATHENA of 
cardiovascular hospitalisations or all-cause death during the trial period; 
 Number of life years gained during and after the clinical trial: based on predicted 
survival for patients alive at the end of the trial, using life tables by age and gender 
adjusted for an AF-specific mortality risk; 
 Number of QALYs gained during and after the clinical trial: based on predicted 
survival weighted with utilities derived from the regression analyses of follow-up data 
in Paper I.  
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Each of the outcome measures is related to some methodological issues that need to be taken 
into account. An outcome such as events avoided is very specific to the data at hand, and does 
not allow comparison with results even for other AF interventions assessed using other 
outcomes, e.g. time to AF recurrence. Moreover, as the event in this case included 
cardiovascular hospitalisations, which were also an important cost item in the analysis, there 
is a risk of double-counting its impact due to inclusion as part of both costs and effects.  
The extrapolation of survival beyond the trial timeframe for the estimation of life years 
gained is linked to certain assumptions. Often, the mortality observed in clinical trials is 
lower than can be expected in natural history cohorts, due to selected patient populations. In 
this case, use of a parametric regression model to predict survival after the end of the trial 
would have overestimated the number of remaining life years. Therefore, life tables were 
used instead, which do not require any distributional assumptions. These were multiplied by 
an AF-specific mortality risk derived from a similar patient population. No further benefit of 
treatment was assumed after the trial (when treatment was assumed to stop). In the absence of 
follow-up data, this can generally be seen as an acceptable assumption. The only exception 
would be if treatment discontinuation were related to some kind of rebound effect, i.e. 
patients discontinuing treatment in the active arm were to progress faster than those in the 
comparison group. If that were the case, the benefit of treatment would have been 
overestimated.  
As neither HRQoL nor utilities were collected as part of ATHENA, QALYs could only be 
estimated through the use of external data sources. The results from the Euro Heart Survey in 
AF allowed estimation of utilities based on adjustment for known covariates in patient groups 
covered by both studies. As the underlying samples were different e.g. with regards to AF 
type (permanent AF was not part of ATHENA), there could potentially remain a risk of 
underestimation of utilities when applying the regressions based on the Euro Heart Survey.  
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5 RESULTS 
5.1 DETERMINANTS OF UTILITY IN ATRIAL FIBRILLATION (PAPER I) 
At baseline, mean utility was 0.751 (SD 0.269); at follow-up this was slightly higher at 0.779 
(SD 0.253). Amongst those who completed the EQ-5D at both time points, the average 
improvement in utility was 0.013 (SD 0.261). Patients with permanent AF had the lowest 
utility regardless of measurement occasion. 
The dimension of mobility was most affected in the sample, with 44% and 40% reporting 
some or severe problems at baseline and follow-up, respectively. Self-care was least affected, 
with 15-19% reporting some or severe problems over time. The distribution of responses 
across severity levels for the EQ-5D descriptive system is shown in Figure 15. The overall 
severity of problems had lessened at 1-year follow-up, which is likely a reflection of the 
measurement setting.  
Figure 15: Distribution of responses by severity levels in the EQ-5D dimensions for 
AF patients at baseline and 1-year follow-up (adapted from Berg et al., 2010) 
 
At baseline, increasing age, female gender, domestic status outside the own home (e.g. 
nursing homes or homes for the elderly), existing comorbidities (including diabetes, previous 
stroke), as well as symptoms of AF, CHF or angina were all associated with reduced utility. 
Amongst these, previous stroke and CHF symptoms had the strongest impact. Regular 
physical activity had a positive effect on utilities. Utilities also differed by AF type, with 
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paroxysmal and permanent AF having significantly lower utilities than those with a first 
detected episode (reference group).  
At follow-up, major adverse events during the follow-up period, specifically stroke, 
myocardial infarction and CHF, led to large decrements in utility. Presence of AF symptoms 
at follow-up was also a significant negative driver of utility. Similar patterns as at baseline 
were seen for some of the variables, e.g. age and gender. To account for the important role of 
utility at baseline for development over time, determinants of baseline utility were included in 
the follow-up model regardless of statistical significance.  
5.2 ROLE OF DIFFERENT OUTCOME MEASURES IN COST-EFFECTIVENESS 
ANALYSES OF A NEW TREATMENT FOR ATRIAL FIBRILLATION (PAPER 
II) 
During the ATHENA trial, there were on average 0.51 cardiovascular hospitalisations per 
patient in the dronedarone arm, compared to 0.69 in the placebo arm. Including all primary 
endpoint events (i.e. cardiovascular hospitalisations and death from any cause), there were 
0.18 fewer events in the dronedarone arm. When extrapolating survival beyond the trial 
period using AF-adjusted life tables (with a hazard ratio of 1.66), expected survival was 0.22 
life years higher for patients with dronedarone, corresponding to 0.13 QALYs. Table 16 
summarises the mean effects for the different outcome measures per trial arm, showing both 
undiscounted and discounted results.  
Table 16: Mean effects per patient during the trial period (95% CI) (Berg et al., 2013) 
 Dronedarone  Placebo  
Undiscounted    
Cardiovascular hospitalisations (number of events) 0.51 (0.47-0.55) 0.69 (0.64-0.74) 
Events (CV hospitalisations and death from any 
cause) 
0.56 (0.52-0.61) 0.75 (0.69-0.80) 
Expected survival (years) 10.89 (10.66-11.13) 10.67 (10.44-10.91) 
Expected quality-adjusted survival (QALYs) 8.62 (8.42-8.82) 8.48 (8.28-8.69) 
Discounted 5%   
Expected survival (years) 8.21 (8.08-8.34) 8.08 (7.95-8.21) 
Expected quality-adjusted survival (QALYs) 6.50 (6.39-6.61) 6.41 (6.29-6.53) 
Notes: CI=confidence interval, CV=cardiovascular, QALY=quality-adjusted life year 
Overall, mean undiscounted costs per patient were CAD$694 higher in the dronedarone than 
placebo arm over the trial period (CAD$7402 vs. CAD$6708, respectively), which was due 
to higher treatment costs. These were to some extent offset by savings for cardiovascular 
hospitalisations, examinations and procedures, and other concomitant medications. The 
resulting base case ICERs were the following for the different outcomes:  
 Using no discounting: CAD$3784 per event avoided, CAD$3141 per life year gained 
and CAD$5190 per QALY;  
 Using 5% discount rate: CAD$3807 per event avoided, CAD$5204 per life year 
gained and CAD$7560 per QALY.  
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Amongst the different scenarios tested in sensitivity analyses, those relating to changes in 
assumptions and sources for survival extrapolation or utilities had limited impact on overall 
results. The largest impact was seen when using the lowest and highest costs per case mix 
group, with dronedarone treatment becoming the dominant strategy when the highest costs 
were used.  
5.3 DETERMINANTS OF UTILITY IN CHRONIC HEART FAILURE (PAPER III) 
Amongst the sampled CHF patients, the dimensions for which the largest proportion of 
patients reported some or severe problems were mobility (48%), pain/discomfort (51%) and 
anxiety/depression (44%). Mobility, self-care and anxiety/depression were negatively 
affected when comparing to a similar age group (70-79 years) in the Swedish population 
(Burstrom, Johannesson & Diderichsen, 2001), whilst slightly fewer CHF patients reported 
some or severe problems with usual activities compared to the general population (Figure 
17).   
Utility at baseline was negatively affected by female gender, increasing age, increasing 
NYHA class, comorbidities (including lung disease and diabetes), and use of nitrates, 
antiplatelets or diuretics. For LVEF, those with HFPEF had a significantly lower utility than 
those with HFREF. Higher systolic blood pressure and haemoglobin levels were associated 
with increased utility, as were use of angiotensin converting enzyme inhibitors/angiotensin 
receptor blockers and beta-blockers. NYHA class was the single most influential determinant. 
We also identified a significant interaction between age category and NYHA class, whereby 
patients in the youngest age group were more severely affected by worse NYHA status than 
older patients.  
In this data set, the OLS model performed slightly better than the two-part model on a 
population level and for capturing utility ranges. There was a tendency for the two-part model 
to generate somewhat more precise estimates on the individual level.  
There was a noticeable loss to follow-up over one year (34% amongst those with information 
on the EQ-5D), which is a reflection of the high mortality and disease progression seen with 
CHF. Within the sample who filled in the EQ-5D at both time points, absolute change in 
utility over time was driven by gender, age and, measured at inclusion, NYHA class, disease 
duration, systolic blood pressure, ischaemic heart disease, lung disease, angiotensin 
converting enzyme inhibitors/angiotensin renin blockers and antiplatelets.  
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Figure 17: Distribution of responses by severity levels in the EQ-5D dimensions for 
CHF patients at inclusion, the general Swedish population (16-84 years) and 
comparable age group (70-79 years)  
 
Notes: *Only moderate or severe problems reported for 70-79 year olds.  
5.4 IMPACT OF HEALTH-RELATED QUALITY OF LIFE ON PROGNOSIS IN 
CHRONIC HEART FAILURE (PAPER IV) 
Physical mobility and emotional reactions were identified as the two NHP dimensions that 
contributed most information to the factor model, and were thus used in subsequent analyses. 
There was a clear and significant relationship between different strata of the physical activity 
dimension and time to death and time to rehospitalisation, as illustrated in Figure 18. This 
was also confirmed as part of the multivariate survival models, where physical mobility was a 
significant independent predictor for all four outcomes, with every 1% worsening (increase) 
resulting in a 1-2% increase in the hazard ratio of being hospitalised or dying. Emotional 
reactions were an additional independent predictor for all-cause hospitalisations, leading to a 
1.3% increase in the hazard ratio with every 1% worsening.  
As for previous studies in this field, it should be noted that the prognostic impact of HRQoL 
on outcomes has been shown in a statistical sense. The underlying causal mechanism between 
physical mobility and outcomes in CHF may be explained by the strong link to oxygen 
uptake and exercise capacity, which have previously been shown to be predictors of mortality 
(Mejhert et al., 2002). The mechanisms around other HRQoL domains, such as emotional 
reactions, and rehospitalisations warrant further research.  
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Figure 18: Kaplan-Meier curves for all-cause mortality and hospitalisations by 
quartiles of NHP physical mobility score (Berg et al., 2014) 
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5.4.1 Previously unpublished results: mortality impact of health-related 
quality of life measured at 1-year follow-up visit in outpatient care 
As part of the OPTIMAL study, clinical and functional variables were collected at scheduled 
outpatient visits 6, 12 and 18 months after the qualifying admission. We hypothesised that 
there may also be an impact of HRQoL on prognosis when measured in an outpatient setting 
following the acute phase. To test this, we applied the same analytical approach as in Paper 
IV to the data collected as part of the 12-month follow-up. We chose this timeframe to allow 
for completed titration of medications and clinical stabilisation following the index 
hospitalisation. As the majority of first readmissions occurred during the first year of follow-
up, we only focused on mortality in these analyses.  
At 12-month follow-up, 150 patients had completed the NHP. Mean age was 76.2 years (SD 
6.9), and 59% were male. Similar to baseline, physical mobility and emotional reactions were 
the most informative factors of the NHP. The prognostic value of HRQoL remained 
significant for cardiovascular mortality; in fact, physical mobility measured at 12 months in 
outpatient care had almost the same magnitude of effect as seen for the baseline measurement 
(Table 19). No significant impact of HRQoL on all-cause mortality was found using 12-
month data, which could be due to the small sample size, but also due to competing risks 
from other events as patients survive the first year following the index hospitalisation. These 
results suggest that the impact of HRQoL, and specifically physical mobility, on 
cardiovascular mortality may be similar regardless of timing and setting of assessment, which 
provides useful information for clinical applications.  
Table 19: Final model specifications for predictors of cardiovascular mortality, using 
measurements from 12-month follow-up visit (n=112) 
Covariate Hazard ratio 95% CI p 
Age at follow-up (years) 0.991 0.922 1.064 0.794 
Female gender 0.445 0.216 0.917 0.028 
eGFR at follow-up (ml/min) 0.974 0.952 0.997 0.029 
BNP at follow-up (ng/l)* 3.796 1.846 7.803 0.000 
Physical mobility at follow-up 1.013 1.000 1.026 0.041 
Notes: *Log-transformed variable 
BNP=brain natriuretic peptide, eGRF=estimated glomerular filtration rate 
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6 DISCUSSION 
6.1 CRITICAL EVALUATION OF STUDY METHODS AND FINDINGS 
Table 20 summarises the key strengths and limitations of Papers I-IV, together with 
information on how limitations were sought to be addressed and, where relevant, the potential 
impact on results.  
Table 20: Summary of key strengths and limitations of Papers I-IV 
Study Strengths Limitations 
Paper I: 
Utilities in 
AF 
1. Large international sample 
covering broad spectrum of AF 
(n=5050) – previously more 
narrow samples 
2. EQ-5D-based utilities useful for 
economic evaluations 
3. Use of statistical methods 
recommended for utility data at 
the time (CLAD), comparison 
with standard OLS models 
1. Large share of specialised or interested 
centres, i.e. more severely ill patients 
2. Patients responding at baseline more 
healthy, i.e. potential underestimation of 
some effects 
3. Stepwise regression may be seen as 
mechanistic, potential non-linear terms 
were not tested for – however, findings 
are in line with earlier studies and post-
hoc analyses using OLS with robust 
standard errors 
Paper II: 
ATHENA 
WTA 
1. Cost-effectiveness based on 
patient-level data (n=4628) with 
morbidity-mortality endpoints – 
relevant in payer and clinical 
decision-making  
2. Results stable across range of 
sensitivity analyses and 
assumptions, incl. post-hoc 
subgroup analyses for PALLAS 
3. Conservative estimates due to 
exclusion of e.g. indirect costs  
1. Multinational trial covering different 
health care systems – however, 
heterogeneity test not significant 
2. Lack of utility data from trial population – 
addressed by adjusted results from Paper I 
3. Full-sample estimation did not adjust for 
right-censoring of cost data, leading to 
underestimation of overall costs (Raikou 
& McGuire, 2004). As follow-up did not 
differ between treatment arms, the higher 
event rate in the placebo group would 
imply a bias against dronedarone. In 
similar analysis for AFFIRM, full-sample 
estimation did not change cost-
effectiveness outcomes, but 
underestimated uncertainty of decision 
(Fenwick et al., 2008)  
Paper III: 
Utilities in 
CHF 
1. Large sample with national 
coverage (n=5334) 
2. New information on important 
patient subgroups, incl. different 
levels of LVEF 
3. Comprehensive statistical 
modelling approach, incl. results 
based on two different value sets 
(Sweden and UK) 
1. Predominance of hospitalised, i.e. more 
severe, patients – adjustment for e.g. 
NYHA class in analyses 
2. Lack of comprehensive data on changes in 
clinical parameters and events after 
inclusion 
3. Generic HRQoL not as responsive to 
clinical change as disease-specific 
instruments – however, reflects clinically 
relevant differences between groups (e.g. 
NYHA class) 
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Notes: AF=atrial fibrillation, CHF=chronic heart failure, CLAD=censored least absolute deviations, 
HRQoL=health-related quality of life, HTA=health technology assessment, LVEF=left ventricular ejection 
fraction, NHP=Nottingham Health Profile, NYHA=New York Heart Association, OLS=ordinary least squares 
6.1.1 Representativeness of study samples 
An important aspect in the use of these study findings is the representativeness of the study 
samples for the patient populations of interest. In the Euro Heart Survey underlying Paper I, 
patients were recruited from cardiology clinics chosen to represent local medical practice 
(Nieuwlaat et al., 2005). A large share of patients was included in university centres (46%) 
and specialised centres (14%), indicating an overrepresentation of highly specialised clinics 
and those with an interest in AF research, which is also mirrored in the fact that 10-15% of 
patients were participating in clinical trials. Overall, 86% of patients had at least one stroke 
risk factor and 70% had AF symptoms at inclusion despite treatment. This could mean that 
our estimated utilities may have been lower than for an AF population including also less ill 
patients. However, patients filling in the EQ-5D at baseline were on average younger and 
healthier than those with incomplete information, which in turn may have led to an 
underestimation of the effect of different covariates. Moreover, when comparing to a wider 
AF population, patients seen in primary care are generally older and more frequently have 
permanent AF than those in a more specialised setting (Kirchhof et al., 2014), which might 
imply that patients from primary care who were not covered by the survey not necessarily 
would have had higher utilities.  
When applying the utilities at follow-up from Paper I in the trial-based evaluation of 
ATHENA in Paper II, we adjusted for some of the known differences between the 
populations through available covariates, e.g. regarding age (mean age five years higher in 
ATHENA), gender (5% fewer men in ATHENA) and underlying heart disease (e.g. 21% 
with CHF history in ATHENA vs. 34% in Euro Heart Survey) (Hohnloser et al., 2009; 
Nieuwlaat et al., 2005). However, permanent AF was excluded in ATHENA, which may 
have led to an underestimation of baseline utility when applying the utility weights from 
Paper I. Furthermore, patients recruited into the trial are by nature usually not representative 
of patients seen in clinical practice. For example, the relatively high age limit in ATHENA (at 
least 70-75 years, depending on risk factors) means that in participating countries with lower 
average life expectancy, e.g. Russia, there would have been a clear overrepresentation of 
“healthy survivors” in the trial. This would probably not have occurred to the same extent in 
the observational Euro Heart Survey. Notwithstanding differences in study methods and 
patient characteristics, mortality outcomes in the two samples were relatively similar. In the 
Paper IV: 
HRQoL 
and 
prognosis 
in CHF 
1. Long-term follow-up (8-12 years) 
of mortality and rehospitalisations 
2. Well characterised sample in 
terms of clinical variables, 
neurohormonal activation and 
echocardiographic measures 
3. Factor analysis allowed study of 
impact of specific HRQoL 
dimensions on outcomes 
1. Small sample (n=177) 
2. Patient sample treated with optimised 
drug therapy as of 1996-1999 – inherent 
to retrospective long-term studies 
3. NHP not often used today – however, 
results reflective of other HRQoL 
instrument findings, incl. disease-specific 
measures 
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Euro Heart Survey, 1-year mortality was 5.3%, being highest in permanent AF (8.2%) and 
lowest in paroxysmal and persistent AF (3.5% and 3%, respectively) (Nieuwlaat et al., 2008). 
By comparison, in the high risk population with paroxysmal and persistent AF seen in 
ATHENA, 5-6% of patients died during the trial (mean duration 21 months) (Hohnloser et 
al., 2009).  
The patient sample used for the analyses in Paper III was largely based on patients included 
in hospitals or in specialised outpatient care in Sweden. However, a recent Swedish registry 
analysis estimated that about 17% of HF patients are managed solely in primary care 
(Zarrinkoub et al., 2013). In reference to this population-based study, our sample is probably 
not representative of patients in the oldest age groups, women in general, or those managed 
only in primary care. The mix of comorbidities was also different in our sample. Finally, due 
to severity, NYHA class IV patients were also most likely underrepresented in our sample. 
These factors could have led to an overestimation of utilities for an overall CHF population in 
terms of age, gender and functional status, and possibly an underestimation due to the 
predominant inclusion from hospitals.  
Patients in Paper IV were part of a randomised study evaluating a nurse-monitored 
management programme at a university hospital in Sweden during 1996-99. The patient 
sample focused on HFREF in NYHA classes II-IV, and received optimised medical therapy 
at the time of study. In comparison to current practice, patients had lower treatment rates with 
beta-blockers and renin angiotensin system blockers (Dahlstrom, Edner & Jonsson, 2012). 
The study is thus not suited for predicting mortality in a HFPEF population or those treated 
with contemporary drugs, where the relationship between HRQoL or utilities and long-term 
outcomes requires further study.  
6.1.2 Meaningfulness of health-related quality of life measurements 
For applications in their work, clinicians and health care decision-makers need information 
on the clinical relevance of HRQoL results for differentiating between appropriate patient 
groups and detecting changes within groups or individuals over time. In this context, the 
responsiveness of HRQoL instruments should be taken into consideration.  
Inherently, disease-specific instruments are more responsive to clinical changes than generic 
instruments; however, the latter may be more suited for the study context, provided that they 
also can capture important differences between groups or over time. In HFREF, the KCCQ 
has been shown to be more sensitive to clinical changes than the RAND12 (similar to the SF-
12) physical and mental component scores and the EQ-5D, when using either the UK or US 
value sets (Eurich et al., 2006). A review of studies investigating the association between 
HRQoL and morbidity and mortality in CHF and coronary artery disease concluded that in 
CHF, physical health status measured with disease-specific instruments was better suited for 
outcome prediction than generic instruments due to fewer insignificant results (including SF-
36, NHP, EQ-5D); however, in coronary artery disease, there was no difference between 
instrument types (Mommersteeg et al., 2009). In contrast, based on our analyses in Paper IV, 
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we found that the generic NHP instrument, and especially its physical domain, provided 
significant prognostic value both for mortality and rehospitalisations, even in our 
comparatively small sample. Interestingly, the impact of HRQoL on the hazard for mortality 
in our study was similar to the one seen in a larger longitudinal study using the MLWHFQ 
(Lupon et al., 2013), which may indicate that the measured impact is similar for the two 
generic and disease-specific instruments. In a cross-sectional study of HF outpatients, a 
relatively high correlation was found between MLWHFQ summary and EQ-5D index scores 
(de Rivas et al., 2008), which suggests that the EQ-5D may be a valid and acceptable method 
for measuring HRQoL in these patients, also owing to its simple and fast administration. Our 
results in Paper III support and extend this finding, as we saw a clear distinction between e.g. 
NYHA classes when using the EQ-5D in mainly hospitalised patients.   
To our knowledge, there are no studies evaluating generic vs. disease-specific instruments in 
AF that provide a similar context for our findings in Paper I. Instead, previously established 
minimally important differences for the EQ-5D may be used as a reference point. For the UK 
value set, the mean minimally important difference has been estimated at 0.08 using 
instrument-defined health transitions (Luo, Johnson & Coons, 2010). In this light, our results 
in Paper I would mean that clinically relevant differences were found especially for symptom 
burden and major clinical comorbidities at baseline and events during follow-up (e.g. stroke, 
myocardial infarction, CHF).   
When comparing different generic HRQoL instruments in patient groups similar to those in 
our studies, previous research in rehabilitation patients with relatively mild conditions, 
including cardiovascular disorders, found that the EQ-5D was less responsive to change than 
the SF-6D, despite a wider spread of health state values. This was deemed to be a likely 
reflection of the smaller amount of possible health states when using the EQ-5D (Moock & 
Kohlmann, 2008). We could not identify any studies testing the responsiveness of the NHP in 
cardiovascular patients. However, in elderly women with femoral neck fractures, a 
comparison with the EQ-5D showed that both instruments had good internal and external 
responsiveness, while the EQ-5D had the advantage of already providing sufficient 
information when used on its own for discriminating between patients according to the 
external clinical criterion of fracture displacement (Tidermark & Bergstrom, 2007).  
In summary, we found that the generic EQ-5D and NHP instruments were able to distinguish 
between different groups of patients, also over time. In AF, the EQ-5D was able to detect 
differences between different symptoms and comorbidities that can be deemed as clinically 
relevant, both at baseline and after one year (Paper I). In CHF, we also found that the EQ-5D 
was able to distinguish between clinically relevant patient groups (Paper III). Moreover, the 
NHP instrument allowed stratification of patients in terms of prognosis, both when measured 
at baseline hospitalisation (Paper IV) and at 1-year follow-up in outpatient care (Section 
5.4.1). Depending on the type and amount of HRQoL information required, these generic 
instruments can thus provide informative results for use both in clinical practice and in 
economic evaluations.  
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6.1.3 Considerations when using utilities from different studies 
As outlined in Section 2.2.1.2, different HRQoL instruments and valuation techniques lead to 
different utility estimates. This also needs to be borne in mind when using the results from 
Papers I and III. As an illustration, Figure 21 summarises utility values by NHYA class in 
CHF from previous studies (described in Section 2.3.3) and Paper III. Several observations 
can be made based on this: 
 In all studies, there is a clear inverse association between increasing NYHA class and 
utilities; 
 Utilities obtained with the same method in different samples, e.g. time trade-off 
(Alehagen et al., 2008; Lewis et al., 2001) or EQ-5D (Gohler et al., 2009; Paper III), 
do not necessarily have the same levels or follow the same slope;  
 Converseley, utilities derived in different settings and based on different value sets or 
valuation techniques may still yield similar estimates (e.g. Alehagen et al., 2008; 
Gohler et al., 2009 and Swedish tariff in Paper III); 
 Different value sets for the EQ-5D can have a large impact on utilities (Paper III); 
 Methods allowing for negative utilities (HUI-3, UK tariff for EQ-5D) tend to lead to 
lower utilities across health states.  
Figure 21: Comparison of utilities by NHYA class in CHF for different types of 
elicitation methods and samples 
 
Notes: Paper III – utilities derived for men, 70-79 years, other variables at reference level 
These observations represent the first comparison of existing utility values in CHF. They add 
to other research around the impact of measurement and analysis options on health state 
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utilities. The impact of value sets derived in different countries and through different 
techniques has been demonstrated both on a general level (Knies et al., 2009) and for specific 
diseases (e.g. in rheumatoid arthritis, see Karlsson et al., 2011). Even when using value sets 
from the same country, the choice of instrument and scoring algorithm has been shown to 
impact on the predicted quality-adjusted survival, both in terms of absolute levels and in 
terms of incremental changes (Sorensen et al., 2012). The implications of selecting a specific 
value set can thus be profound, as the slope and level of the utility curves across health states 
has a direct impact on QALYs associated with different treatment strategies. For example, the 
use of a different value set with a smaller slope in Paper I would most likely have led to lower 
incremental QALYs in Paper II. Instead, when comparing dronedarone to other interventions 
in the same indication, the effect of treatment on survival would have received a 
proportionally larger weight.  
6.2 THE ROLE OF HEALTH-RELATED QUALITY OF LIFE AND UTILITIES IN 
PUBLIC HEALTH 
6.2.1 Health policy applications: use by payers 
6.2.1.1 Established use in payer decisions – example of dronedarone 
In many countries, HRQoL and utilities are part of the evidence considered by decision-
makers in reimbursement authorities. On one end of the spectrum, they may be seen as part of 
the clinical evidence, in that they are potential outcome measures for clinical effectiveness. 
On the other end, utilities can be required to obtain QALYs as a summary measure in an 
economic evaluation. In this thesis, Papers I, II and III provide evidence that would be used in 
the latter type of decision-making framework. Papers I and III can be used as sources for 
economic evaluations, while Paper II illustrates a direct application of the findings from 
Paper I that was part of the health economic evidence for dronedarone. The trial-based 
analysis was complemented by modelling studies (e.g. Akerborg et al., 2012; Nilsson et al., 
2013), which also used findings from Paper I. During the analyses for Paper II, new safety 
results became available for dronedarone as part of the PALLAS trial, which led to a 
restriction of its indication. To reflect this, a post-hoc subgroup analysis was performed on 
patients in ATHENA, which provided important sensitivity results.  
In May 2010, the Canadian Expert Drug Advisory Committee (CEDAC) finally 
recommended that dronedarone should not be listed. Its reasons were the uncertainty of the 
therapeutic benefit of dronedarone compared to amiodarone, together with a higher price, 
lack of positive rhythm outcomes and lack of HRQoL data from the clinical trial programme 
(Canadian Agency for Drugs and Technologies in Health, 2010). This decision was in 
contrast to the treatment recommendations by the Canadian Cardiovascular Society and 
European Society of Cardiology, even after the restrictions in the use of dronedarone.  
NICE in the UK has closely integrated QALYs into its decision-making. In its preliminary 
guidance, NICE rejected dronedarone due to lower effectiveness and higher costs compared 
to existing AF treatments (McKenna et al., 2012). However, the subsequent consultation 
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process with clinical experts and patient representatives showed strong disagreement with the 
initial decision, and highlighted the need for clinical alternatives to available antiarrhythmic 
treatment. This led to a final recommendation by NICE for dronedarone to be used as a 
second-line option for patients with non-permanent AF and at least one cardiovascular risk 
factor.  
In the NICE appraisal, the Evidence Review Group commented on the utility data used in the 
UK model. It voiced concerns about the application of utility weights from a single source 
(Euro Heart Survey), and specifically the process of arriving at this source, since there was no 
reporting of a systematic review and the values were not placed into a context of other studies 
or UK population norms. When comparing to population norms, the Evidence Review Group 
saw a risk of potential overestimation of the treatment effect of dronedarone. Therefore, it 
tested to estimate utility decrements of specific health states instead and applied these to UK 
population values. This sensitivity analysis based on a post-hoc adjustment turned out to have 
a limited impact on the ICER (McKenna et al., Centre for Reviews and Dissemination and 
Centre for Health Economics, 2009).  
In the reimbursement decision by the Swedish TLV, the agency followed the indication for 
dronedarone, limiting it to patients with non-permanent AF and at least one cardiovascular 
risk factor (previous stroke or transient ischaemic attack, hypertension, diabetes, age above 
75 years). In addition, TLV requested follow-up with real-world evidence on concomitant 
treatment, stroke risk assessment and clinical outcomes (Tandvårds- och 
Läkemedelsförmånsverket, 2011). In relation to the Canadian example, it is interesting to 
note that treatment guidelines in Sweden take health economic findings into account, where 
the cost per QALY is one of several factors weighing into an overall priority grading for 
different treatments in a given indication (Grip et al., 2011).  
The Institute for Quality and Efficiency in Health Care (IQWIG) in Germany is an example 
of an authority that does not primarily use utilities or QALYs in its decision-making. Instead 
of effectiveness, IQWIG uses the term “benefit”, which is assessed in relationship to costs 
(Institute for Quality and Efficiency in Health Care, 2009). Benefit may be defined in a more 
narrow sense (medical benefit) or a wider sense (including “value” aspects). IQWIG does not 
recommend any specific instrument or procedure for measuring benefits. Since economic 
evaluations are not used for allocating resources across different therapeutic areas in 
Germany, it is possible to use different benefit measures in different therapeutic areas. 
Benefit may be quantified using clinical (including HRQoL), responder or aggregated 
measures. QALYs are mentioned as one potential example of aggregated measures, which 
may be used within an indication if deemed suitable. Rather than WTP thresholds for 
QALYs, IQWIG uses an “efficiency frontier” by therapeutic area in its decision-making. 
Since IQWIG has not published any evaluation of dronedarone, it is not possible to state what 
specific evidence regarding benefits would have been considered in this case. In general, 
HRQoL measures or utilities could be used for an indication-specific assessment; at the same 
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time, it would also be possible to use non-preference based HRQoL measures to demonstrate 
benefit. 
6.2.1.2 Newer applications in quality of care initiatives 
An interesting development is the use of QALYs as an aggregate measure to assess quality of 
care. Traditionally, this has been performed on the basis of selected process indicators, e.g. 
number of tests performed per patient and year, or clinical indicators, such as mortality. Some 
examples of the wider application of QALYs have been found in the US. In the area of 
diabetes risk factor control, QALYs were used to assess therapeutic value across different 
medical centres and were found to be a more useful and informative measure than levels of 
control for individual risk factors (Schmittdiel et al., 2008). In a study on the quality of acute 
hospital care in coronary artery bypass grafting, utility weights were integrated with more 
traditional performance measures (e.g. mortality, complications) to derive a composite 
QALY measure that was able to take different surgical complications and long-term 
outcomes into account (Timbie et al., 2009).  
In a nationwide context, HRQoL has since 2009 been included as part of standard data 
collection for pre- and post-surgery (knee, hip, hernia, varicose veins) in the UK. The EQ-5D 
and disease-specific measures have been recommended as patient-reported outcomes 
measures. This initiative is also being extended to other indications (Black, 2013). The 
information can be used to aid in clinical management of individual patients, assessment and 
comparison of health care providers and for evaluating treatment practices within a given 
indication.  
In Sweden, patient-reported outcomes measures are collected as part of several of the 
numerous quality registers (such as the Swedish Heart Failure Registry used in Paper III). In 
2014, 38 quality registers were using the EQ-5D as part of their regular data collection (not 
counting pilot studies), while seven were using the SF-36 and 16 were using disease-specific 
measures (PROM center, 2014). In a recent report for the National Board of Health and 
Welfare (Nilsson, 2014), no recommendations were given yet as to which measures should be 
used, because it was deemed that further development work and critical evaluation was 
needed, e.g. on the value of national comparisons, and different methodological options 
regarding instruments and analysis. As a case in point, the Swedish Heart Failure Registry is 
collaborating with the national Patient Reported Outcome Measures (PROM) centre in 
Linköping to further develop the methods around the use of patient-reported outcomes in this 
registry.  
In light of these developments, many methodological questions become relevant, e.g. 
regarding suitable instruments, valuation methods and analysis of outcomes. Since the wide 
range of available approaches can lead to markedly different results, development of a 
“reference case” as suggested for the QALY (Drummond et al., 2009) would seem to be 
crucial, even more so because these are challenging concepts to communicate to wider, non-
specialist audiences. As it is likely that such a reference case would have to remain relatively 
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general, normative choices will probably still be required at a decision-maker level (in 
Sweden e.g. TLV, National Board of Health and Welfare, regional drug committees).  
6.2.2 Prognostic markers in clinical practice 
In clinical practice, potential applications of QALYs could be to measure patient health 
status, compare individuals against reference populations and measure change over time in 
individuals and patient groups (Kind et al., 2009). This is certainly also true for HRQoL.  
Prognostic factors may also be used in economic evaluations to stratify treatment 
effectiveness. For example, in the economic models for dronedarone, the CHADS2 score was 
used to stratify treatment effectiveness on all-cause mortality by different stroke risk levels 
(Akerborg et al., 2012; McKenna et al., 2012; Nilsson et al., 2013).  
While the relevance of HRQoL for prognosis has been quite extensively studied in CHF, this 
has not been the case in AF. Recently published analyses from a QoL sub-study of AFFIRM 
(Schron, Friedmann & Thomas, 2014) showed that HRQoL measured with the generic SF-36 
instrument, and in particular its physical component score, was a significant predictor of both 
1-year mortality and hospitalisation in AF patients. In addition, the mental component score 
was a separate predictor for hospitalisations. Thus, the prognostic value of HRQoL is worth 
further research in AF, and probably also in other chronic indications.  
In light of the findings of Paper IV and previous research, it could be worth to explore 
possibilities for including HRQoL in risk prediction models to a larger extent than has been 
done to date. For wider use in clinical practice, the following aspects should be considered:  
 The HRQoL scale should be able to capture clinically important changes, as discussed 
in Section 6.1.2; 
 The prediction parameters should be quite easily available as part of standard care, 
which in some countries may see an increasing uptake of HRQoL information 
through e.g. quality of care initiatives as described in the previous section; 
 A comprehensive set of significant predictors, including clinical parameters, e.g. 
physician assessments or diagnostic tests, may improve the precision of the predicted 
outcome; 
 Risk prediction models may be more suited for “pure” clinical endpoints such as 
mortality, as e.g. readmissions are more likely to depend on local health care 
organisation, funding and treatment practices. 
For implementation in clinical practice, standard procedures could be introduced to measure 
HRQoL (e.g. using the EQ-5D) for risk stratification and subsequent follow-up of high-risk 
patients.  
6.2.3 Possible use with patients 
The studies in this thesis have not dealt with direct use of HRQoL or utilities with individual 
patients. Since it is patients’ HRQoL that is investigated, the information can form a natural 
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component when involving patients in evaluation of and decisions regarding their health. 
Shared decision-making aims to promote collaboration between patients and clinicians by 
taking into account best available evidence together with individual patient characteristics 
and preferences (Politi et al., 2013). This is usually focused on clinical comparative 
effectiveness (benefits and risks) of different treatment alternatives. An interesting example 
of possible extensions of this concept to a decision-support system involving utilities is a 
mobile tool that has been tested in a small group of AF patients (Quaglini et al., 2013). The 
tool uses techniques from economic evaluations as part of its decision-making framework, 
including decision trees, Markov models, and patient preference for different health states 
using standard gamble or time trade-off techniques. In this context, one needs to consider 
potential challenges when communicating about concepts such as QALYs, probabilities, 
uncertainty of outcomes and the difference between population means and individual disease 
trajectories.  
6.3 SUGGESTIONS FOR FUTURE RESEARCH 
Based on the studies covered in this thesis and their place in the wider public health context, 
there are several areas that would warrant further research: 
 Compare different generic and disease-specific HRQoL instruments in the same 
patient sample to better understand their responsiveness and ability to capture relevant 
domains – especially in AF, there is a lack of such studies to date, and it would be 
interesting to evaluate some of the recently developed AF-specific instruments in this 
respect; 
 Investigate the value of generic instruments, e.g.the EQ-5D, in detecting change over 
time and providing prognostic information in broad patient samples – this would be of 
interest both in CHF and in AF and could include outcomes such as mortality and 
disease progression;  
 Investigate the relationship between HRQoL/utilities and other covariates in specific 
patient groups for more precise estimates in economic evaluations – in CHF, the link 
between LVEF and HRQoL/utilities is of particular interest; other parameters could 
include disease type (e.g. in AF), symptom levels (also in AF), comorbidities, care 
setting (primary vs. specialist care); 
 Test the development of a risk scoring tool that includes HRQoL together with key 
clinical information for patient groups of interest – this would require external 
validation and could then be used to classify patients according to risk in clinical 
practice and in the evaluation of new therapies; 
 Understand how HRQoL and utilities are used in the health care system and clinical 
decision-making – ideally, the goal would be to generate a common understanding of 
the issues in terms of methods, implementation and communication and how these 
could be approached going forward, e.g. in the context of quality of care initiatives. 
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In general, when deciding on the most suitable study design to address these questions, 
different alternatives should be evaluated in terms of both the type and representativeness of 
data that can be collected and the associated costs and time requirements. Potential options 
include e.g. cross-sectional or longitudinal data collection, as well as use of data from 
national or local registries.  
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7 CONCLUSIONS 
In summary, the studies in this thesis support the use of HRQoL and utilities as a value-added 
part of clinical and economic decision-making, due to their relationship with both clinical and 
economic outcomes. Specifically, the following conclusions can be drawn: 
 In AF patients treated in specialist care, increasing age, female gender, domestic 
status outside the own home, existing comorbidities, and symptoms of AF, CHF or 
angina were associated with reduced utility at baseline, while regular physical activity 
had a positive effect. At 1-year follow-up, significant determinants included AF 
symptoms and major adverse events, including stroke, myocardial infarction and CHF 
(Paper I); 
 The information on determinants of utility can be used in different types of economic 
evaluations, as shown in the cost-effectiveness evaluations of dronedarone (including 
Paper II). The within-trial analysis indicated that dronedarone when used as in 
ATHENA is cost-effective within generally accepted thresholds (base case ICER 
CAD$7560 per QALY), and that this also would hold in the light of subsequent label 
restrictions (Paper II); 
 In CHF patients mainly seen in hospital, utility at baseline was negatively affected by 
female gender, increasing age, increasing NYHA class, preserved LVEF, lung 
disease, diabetes, and use of nitrates, antiplatelets or diuretics. Higher systolic blood 
pressure and haemoglobin levels and use of of angiotensin converting enzyme 
inhibitors/angiotensin receptor blockers or beta-blockers were associated with 
increased utility. A significant interaction between age category and NYHA class 
shows that patients in the youngest age group are more severely affected by 
worsening NYHA status than older patients. In our data set, the OLS model 
performed slightly better than the two-part model on a population level and for 
capturing utility ranges (Paper III); 
 In patients hospitalised with systolic CHF, physical mobility as measured with a 
generic HRQoL instrument was a significant independent predictor for all-cause and 
cardiovascular rehospitalisation and mortality, with every 1% worsening resulting in a 
1-2% increase in the hazard ratio of being hospitalised or dying. Emotional reactions 
were an additional independent predictor for all-cause hospitalisations, with a similar 
impact as physical mobility (Paper IV). Additional analyses suggest that the impact of 
HRQoL, and specifically physical mobility, on cardiovascular mortality may be 
similar irrespective of timing and setting of assessment.  
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